



## Glucagon Receptor Signaling and Glucagon Resistance

Janah, Lina; Kjeldsen, Sasha; Galsgaard, Katrine D.; Winther-Sorensen, Marie; Stojanovska, Elena; Pedersen, Jens; Knop, Filip K.; Holst, Jens J.; Albrechtsen, Nicolai J. Wewer

*Published in:*  
International Journal of Molecular Sciences

*DOI:*  
[10.3390/ijms20133314](https://doi.org/10.3390/ijms20133314)

*Publication date:*  
2019

*Document version*  
Publisher's PDF, also known as Version of record

*Document license:*  
[CC BY](#)

*Citation for published version (APA):*  
Janah, L., Kjeldsen, S., Galsgaard, K. D., Winther-Sorensen, M., Stojanovska, E., Pedersen, J., Knop, F. K., Holst, J. J., & Albrechtsen, N. J. W. (2019). Glucagon Receptor Signaling and Glucagon Resistance. *International Journal of Molecular Sciences*, 20(13), [3314]. <https://doi.org/10.3390/ijms20133314>



Review

# Glucagon Receptor Signaling and Glucagon Resistance

Lina Janah <sup>1,2,†</sup>, Sasha Kjeldsen <sup>1,2,†</sup>, Katrine D. Galsgaard <sup>1,2,†</sup>, Marie Winther-Sørensen <sup>1,2</sup> ,  
Elena Stojanovska <sup>1,2</sup>, Jens Pedersen <sup>1,3</sup>, Filip K. Knop <sup>2,4,5,6</sup> , Jens J. Holst <sup>1,2</sup> and  
Nicolai J. Wewer Albrechtsen <sup>1,7,8,\*</sup>

<sup>1</sup> Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark

<sup>2</sup> Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark

<sup>3</sup> Department of Cardiology, Nephrology and Endocrinology, Nordsjællands Hospital Hillerød, University of Copenhagen, 3400 Hillerød, Denmark

<sup>4</sup> Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark

<sup>5</sup> Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark

<sup>6</sup> Steno Diabetes Center Copenhagen, 2820 Gentofte, Denmark

<sup>7</sup> Department of Clinical Biochemistry, Rigshospitalet, 2100 Copenhagen, Denmark

<sup>8</sup> Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark

\* Correspondence: nicolai.albrechtsen@sund.ku.dk

† Contributed equally to the preparation of the manuscript.

Received: 30 May 2019; Accepted: 3 July 2019; Published: 5 July 2019



**Abstract:** Hundred years after the discovery of glucagon, its biology remains enigmatic. Accurate measurement of glucagon has been essential for uncovering its pathological hypersecretion that underlies various metabolic diseases including not only diabetes and liver diseases but also cancers (glucagonomas). The suggested key role of glucagon in the development of diabetes has been termed the bihormonal hypothesis. However, studying tissue-specific knockout of the glucagon receptor has revealed that the physiological role of glucagon may extend beyond blood-glucose regulation. Decades ago, animal and human studies reported an important role of glucagon in amino acid metabolism through ureagenesis. Using modern technologies such as metabolomic profiling, knowledge about the effects of glucagon on amino acid metabolism has been expanded and the mechanisms involved further delineated. Glucagon receptor antagonists have indirectly put focus on glucagon's potential role in lipid metabolism, as individuals treated with these antagonists showed dyslipidemia and increased hepatic fat. One emerging field in glucagon biology now seems to include the concept of hepatic glucagon resistance. Here, we discuss the roles of glucagon in glucose homeostasis, amino acid metabolism, and lipid metabolism and present speculations on the molecular pathways causing and associating with postulated hepatic glucagon resistance.

**Keywords:** alpha cell; amino acids; diabetes; glucose; hyperaminoacidemia; hyperglucagonemia; liver–alpha cell axis

## 1. Introduction

In the 1920s, Kimball and Murlin reported the existence of a pancreatic factor other than insulin with effects on glucose homeostasis (GLUCose-AGONist [1]) [2]. This factor was later identified as

glucagon (denoted glucagon 1–29) [3]. Glucagon is a peptide of 29 amino acids with a variety of biological actions including, but not limited to, glucose homeostasis [4–6]. A recent PubMed search on glucagon revealed that more than 45,000 articles relating to glucagon have been published, and extensive efforts are currently being made to further study and understand the physiological role(s) of glucagon [4,7].


The biology of glucagon is intriguing not only from a physiological perspective but indeed also from a therapeutic point [1,8,9]. Glucagon receptor antagonism reduces blood glucose in patients with type 2 diabetes, and glucagon co-agonism (with, e.g., an incretin hormone) reduces body weight in overweight type 2 diabetes patients [10]. The complexity of glucagon's suggested diabetogenic effect is greater than anticipated, as antagonizing its actions affects fasting but not postprandial blood glucose levels [11]. This is in contrast to what one may have suspected, as the 'hyperglucagonemia' observed in some type 2 diabetes patients has been reported to be pronounced in the postprandial state (the lack of glucose-induced suppression of alpha cell secretion, which we will come back to later) [12–14]. The impact of glucagon therefore differs between fasting and prandial conditions, at least when it comes to glucose homeostasis. Investigating the physiological actions of glucagon on not only glucose homeostasis but, importantly, also on lipid and amino acid metabolism is needed for understanding glucagon biology at fasting and prandial conditions. Specifically, biased (meaning activation of specific intracellular pathways) targeting of glucagon receptor signaling [15] towards, e.g., hepatic glycogenolysis or gluconeogenesis may potentially represent an 'intelligent pharmacological' approach exploiting, e.g., the glucose lowering effects of glucagon receptor antagonism without its undesired effect on hepatic lipid metabolism (increased liver fat [16]).

The purpose of this review is to assess the key aspects of glucagon receptor signaling not only regarding glucose homeostasis but also with respect to amino acid and lipid metabolism. We will also discuss the evidence and potential relevance of the new concept of hepatic 'glucagon resistance'. We begin this review by introducing the production, secretion, and measurement of glucagon before turning towards glucagon receptor signaling in regards to glucose, amino acid, and lipid metabolism.

## 2. Processing of Proglucagon

The GCG gene, encoding the glucagon precursor proglucagon, is well conserved across species [17]. Proglucagon has 160 amino acids and is expressed in certain neurons of the brain stem, in intestinal L cells, and in pancreatic alpha cells [17]. Several bioactive peptides, including glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2), are cleaved from proglucagon by prohormone convertase(s) in a tissue-specific (or perhaps more accurately enzyme-specific [18]) manner (Figure 1). The differential processing of proglucagon appears to reflect the enzymatic activities of the two prohormone convertases: prohormone convertase 1/3 (PC1/3) and 2 (PC2) [19]. Proglucagon therefore gives rise to a variety of peptides. Thus, throughout the small and large intestine, proglucagon-producing cells termed L cells are located within the epithelium [20,21] in an ideal position to sense the variety of nutrients and microbial products and convey the information to the rest of the body via the secretion of GLP-1, GLP-2, oxyntomodulin, and glicentin, which contribute to the regulation of appetite, bone resorption, gastrointestinal growth, and glucose homeostasis [1,22–25]. With co-expression of PC1/3 (e.g., in intestinal L cells), proglucagon is cleaved to form glicentin, oxyntomodulin, GLP-1, and GLP-2; whereas with PC2 expression as in the alpha cells, proglucagon is cleaved to form mainly glucagon and the so-called major proglucagon fragment [26–28]. In line with this, mice deficient of PC1/3 are incapable of producing GLP-1, while mice deficient of PC2 cannot produce glucagon [29–32].

The absolute selectivity of PC1/3 and PC2 remains a matter of discussion. It has been speculated that metabolic stressors such as type 2 diabetes, obesity, and Roux-en-Y gastric bypass surgery may alter the processing profile of proglucagon both in the pancreas and in the gut, but the extent to which this occurs in humans and the clinical relevance of such changes remain unknown [18].



**Figure 1.** Processing and measurement glucagon. Glucagon (proglucagon 33–61) results from prohormone convertase 2 (PC2)-dependent processing of proglucagon (PG 1–160). In the intestine, PG is processed by prohormone convertase 1/3 (PC1/3) activity to form glicentin (1–69), which may be further cleaved into glicentin-related pancreatic polypeptide (GRPP) and oxyntomodulin (33–69). N-terminal directed antibodies will therefore also cross-react with oxyntomodulin whereas C-terminal antibodies react with proglucagon 1–61, and finally antibodies raised against the mid-region of glucagon will potentially bind to all of the aforementioned peptides. Measurement of glucagon may therefore require a sandwich ELISA targeting both termini.

### 3. Secretion of Glucagon

Glucagon is secreted in response to a variety of metabolic signals [6,33] such as changes in blood glucose concentrations [2,34], certain amino acids [35], perhaps free fatty acids [36], and in response to stress [37] (e.g., activation of the sympathetic nervous system). Here, we shortly discuss some of the currently suggested mechanisms underlying glucose-dependent glucagon secretion. For further insight, please see Ref. [4,38–40].


In humans, blood glucose levels are reciprocally correlated to glucagon secretion, and the potential intrinsic glucose-sensing mechanisms of alpha cells have been studied for decades using a variety of techniques [6,41–43]. As an example, the physiological roles of sodium and potassium channels have been studied in whole islets and isolated alpha cells using electrophysiological techniques (patch clamping). Paracrine factors also play an important role and some have argued that combining or integrating intrinsic and paracrine factors is needed to uncover the enigmatic mechanism of glucose-induced inhibition of glucagon secretion [44,45].

The mechanisms underlying glucose-induced inhibition of alpha cell secretion are still a matter of debate. One of the proposed intrinsic pathways leading to hypoglycemia-induced glucagon secretion is a decrease in the ATP/ADP ratio, which paradoxically slightly increases K<sub>ATP</sub> channel activity, leading to voltage-dependent increased activity of P/Q type calcium channels and a subsequent influx of Ca<sup>2+</sup> [46]. In vivo, another important mechanism may be hypoglycemia-induced activity of the pancreatic sympathetic innervation [47]. The potent regulation of glucagon secretion by glucose from isolated perfused pancreas preparations supports a direct effect of hypoglycemia on the alpha cell [48], unless stimulatory neurons of the intra-pancreatic ganglia are glucose sensitive.

Hyperglycemia-induced attenuation of glucagon secretion may be even more complex due to extra-pancreatic signals such as the glucagonostatic effect of GLP-1 or the glucagonotropic effects

of GLP-2 and glucose-dependent insulintropic polypeptide (GIP), all three of which are secreted in response to the ingestion of carbohydrates. In addition, paracrine signals elicited by glucose, in particular delta cell-secreted somatostatin and beta cell-secreted insulin, may also inhibit glucagon secretion. A recently published study demonstrates that glucokinase, expressed in alpha cells, may play an important role in glucose-regulated glucagon secretion [49,50]. The inhibitory effect of glucose is preserved in whole islets but appears to be lost when alpha cells are isolated and studied selectively [51]. This again points to an important effect of intra-islet factors secreted from the neighboring beta and delta cells. Somatostatin secreted from the pancreatic delta cells and insulin secreted from pancreatic beta cells in response to increased glucose concentrations both inhibit glucagon secretion [52], although this may depend on the experimental setting [53]. Other intra-islet factors have also been implied in the regulation of glucagon secretion: urocortin 3 [54], zinc [55], GABA/L-glutamate [56], gamma-aminobutyric acid [57], amylin [58], and ephrin [59]. Furthermore, several extra-islet signals have been reported to contribute to the regulation of glucagon secretion and include, but are not limited to, GLP-1 [60], GIP [61], GLP-2 [62], ghrelin [63], and gastrin [64]. Finally, the newer class of glucose-lowering drugs for the treatment of type 2 diabetes, sodium-glucose co-transporter 2 (SGLT-2) inhibitors, have been associated with increased plasma glucagon concentrations. The absolute differences in plasma glucagon concentrations between SGLT-2 inhibitor-treated and placebo-treated patients are small (1–1.5 pmol/L) [65,66], and although some have argued for a direct role of SGLT-2 on the alpha cells [67–70], current evidence, which includes the results of glucose clamping, seems to point toward an indirect mechanism by which SGLT-2 inhibition increases renal glucosuria, resulting in significant lowering of blood glucose concentrations that causes a slightly greater alpha cell secretion [71–75]. Whether or not increased plasma glucagon after SGLT-2 inhibition has any clinical impact is currently unknown, but some may argue that increasing hepatic glucose production when combined with reduced glucose reuptake in the kidneys may limit the reduction in blood glucose (and hence clinical efficacy).

Clearly then, changes in glucagon secretion induced by glucose, for instance, depend on the experimental conditions and may differ dramatically between experiments in isolated alpha cells, isolated islets, isolated perfused pancreas preparations, and in vivo. Intra- and extra-islet factors implicated in the regulation of glucagon secretion are summarized in Figure 2.



**Figure 2.** Regulation of glucagon secretion. Several factors regulate the secretion of glucagon; most importantly glucose, amino acids, gastrointestinally derived peptides, the autonomic nervous system (extra-islet regulation), and possibly peptides secreted from the alpha, beta, and delta cells (intra-islet regulation), among which at least the inhibitory action of delta cell-derived somatostatin is well established. Black arrows refer to a stimulatory effect on glucagon secretion and red T bars refer to an inhibitory effect.

#### 4. Accurate Measurement of Glucagon

A major limitation to the study of glucagon physiology and pathophysiology has been the hitherto limited accuracy of many immunoassays used to measure glucagon [76]. Some studies have applied additional analytical techniques such as size-exclusion chromatography and mass-spectrometry for characterization of the measured moiety. Falsely increased glucagon immunoreactivity may be due to degradation of circulating glucagon-containing molecules such as glicentin, oxyntomodulin (in vivo as well as post sampling), or proglucagon with resulting formation of (immunoreactive) glucagon. Another explanation may be insufficient specificity, e.g., cross-reactivity of the antibody/antibodies used in the assay with peptides with related sequences to that of glucagon [77,78]. The term hyperglucagonemia may therefore not in all cases relate to increased plasma concentrations of bioactive glucagon but may as well be ascribed to preanalytical and analytical challenges. The analytical and physiological importance of N-terminally elongated glucagon-like moieties is uncertain [78–80], but part of the concentration of immunoreactive glucagon measured in plasma with the single antibody C-terminal immunoassays may certainly be due to such molecular forms, in particular proglucagon 1–61 [79]. This may be particularly important in patients with impaired kidney function [81].

#### 5. Glucagon Receptor Signaling

##### 5.1. Glucagon and Glucose Homeostasis


A fundamental aspect of glucagon signaling is its role as a regulator of glucose homeostasis [43,82]. Increased plasma glucagon levels result in increased hepatic glucose production [83]. Therefore, glucagon is traditionally known as a counter-regulatory hormone to the hypoglycemic effects of insulin [84]. This balance of glucagon and insulin signaling is thus largely responsible for maintaining physiological euglycemia [85]. In hypoglycemic conditions, glucagon secretion increases, which results in increased hepatic glucose production via a number of cellular mechanisms involving suppression of glycogenesis and glycolysis and stimulation of glycogenolysis and gluconeogenesis [86,87] (Figure 3).

Once glucagon binds its seven transmembrane receptor on the plasma membrane of the cell, it leads to conformational changes that activate  $G_{\alpha s}$ -coupled proteins [83]. This consequently increases cAMP levels via the activation of adenylate cyclase, which in turn stimulates activation of protein kinase A (PKA) and cAMP response element-binding (CREB) protein [87]. CREB is responsible for inducing transcription of glucose 6-phosphatase and phosphoenolpyruvate carboxykinase (PEPCK), both of which contribute to increased gluconeogenesis. Meanwhile, PKA activation results in a number of intracellular events in addition to phosphorylation of CREB [41,86]. Firstly, it phosphorylates (hence activates) the phospho-fructokinase 2 (PFK-2)/fructose 2,6-bisphosphatase (FBPase2) protein. Upon phosphorylation, the PFK-2 activity is inhibited while the FBPase2 activity is activated, leading to increased fructose 6-phosphate levels. This induces gluconeogenesis, while decreased fructose 2,6 bisphosphate levels result in reduced glycolysis [41,86]. Secondly, PKA activates pyruvate kinase, which increases fructose 1,6 bisphosphate levels and thus lower pyruvate levels, which suppresses glycolysis [88]. Thirdly, PKA activates phosphorylase kinase, which, via activated phosphorylase, increases conversion of glycogen to glucose 1-phosphate in addition to inhibiting glycogen synthase, which overall lowers glycogen levels and results in hepatic glucose release [89].

During periods of short-term fasting (less than ~12 h), glucose levels in the bloodstream rely mainly on glycogenolysis, but over time as glycogen stores become depleted, the maintenance of euglycemia increasingly depends on gluconeogenesis [89]. Because the effect of glucagon on gluconeogenesis relies on gene transcription, the physiological effects do not result until hours after glucagon secretion, whereas the stimulatory effect of glucagon on glycogenolysis has observable effects within minutes due to the rapid phosphorylation cascade [90]. Given that gluconeogenesis is a substrate-dependent mechanism and glucagon does not feed gluconeogenesis via provision of, e.g., muscle-derived amino acids (to date no glucagon receptor has been identified on human skeletal cells), other mechanisms, including catecholamines and cortisol [91–93], must act in order to maintain blood glucose during



long-term fasting. However, glucagon stimulates hepatic amino acid metabolism [94], resulting in an increased flux of amino acids into the hepatocytes and is thereby also able to provide substrates in the form of gluconeogenic amino acids. The relative contribution of glucagon to glucose production therefore varies depending on glycogen content and the availability of gluconeogenic substrates in the circulation. This is in concordance with studies showing that during prolonged fasting (when glycogen stores are depleted, and the hepatic glucose production depends on gluconeogenesis), the effect of glucagon on hepatic glucose production is weak [83,91,92]. Glucagon may therefore be ineffective in regards to hepatic glucose production when glycogen stores are exhausted, e.g., during starvation and prolonged exercise [84,88].



**Figure 3.** Glucagon effects on hepatic glucose production. Activation of the glucagon receptor results in adenylyl cyclase activation and cAMP formation. The increase in intracellular cAMP levels activates protein kinase A (PKA), which phosphorylates the transcription factor cAMP-response-element-binding (CREB) protein. CREB induces the transcription of glucose 6-phosphatase and phosphoenolpyruvate carboxykinase (PEPCK), two enzymes that contribute to increased gluconeogenesis. PKA phosphorylates (hence activates) the phospho-fructokinase 2 (PFK-2)/fructose 2,6-bisphosphatase (FBPase2) protein. Upon phosphorylation, PFK-2 activity is inhibited while FBPase2 activity is activated. Glucagon thus lowers the level of fructose 2,6-bisphosphate and increases fructose 6-phosphate levels, which suppresses glycolysis and increases gluconeogenesis. Secondly, PKA phosphorylates pyruvate kinase, resulting in increased fructose 1,6 bisphosphate levels and decreased pyruvate levels, which leads to reduced glycolysis. Most importantly, PKA phosphorylates phosphorylase kinase, initiating the glycogenolysis cascade increasing the conversion of glycogen to glucose 1-phosphate. Finally, PKA phosphorylates and inhibits glycogen synthase (glucose-6-phosphatase). The red arrows indicate inhibitory actions of glucagon receptor signaling while black arrows indicate stimulatory actions of glucagon receptor signaling.

This is exemplified by the findings of attenuated glucose production in response to exogenous glucagon after one week of low carbohydrate diet (LCD) compared to the response after a week of high carbohydrate diet (HCD) in patients with insulin pump-treated type 1 diabetes [95,96]. The lowered glucose production in response to glucagon is likely to be due to the reduced storage of hepatic

glycogen in the LCD group [97,98]. However, acute glucagon administration after a period of LCD caused a significantly higher increase in free fatty acid (FFA) and ketone body plasma concentrations compared to glucagon administration after the HCD. This indicates that the LCD may have promoted the use of fat over carbohydrates, resulting in increased fat oxidation and ketogenesis [99], supporting the conclusion that glucagon regulates glucose homeostasis mainly through glycogenolysis rather than gluconeogenesis. These results suggest that diet carbohydrate content must be accounted for when treating hypoglycemia with low-dose glucagon, as the amount of glycogen is crucial for the effect of glucagon on blood glucose concentrations [100].

The above-mentioned studies are of clinical interest as glucagon is used to treat hypoglycemia—in most cases due to exogenous hyperinsulinemia (iatrogenic). Furthermore, low dose glucagon injection is currently being investigated in connection with the development of dual-pumps (glucagon + insulin infusion) [101–105]. Recent studies suggest that the amount of glucose produced (assumable by hepatic glucose production) after glucagon injection may not be influenced by body weight—in the same study, insulin levels across patients and testing time points remained constant. Therefore, the capacity for glucagon to appropriately regulate plasma glucose concentrations may, as suggested, not be affected by body weight and hence the existence of glucagon resistance (see the Section regarding glucagon resistance). In contrast, studies in animal models of hepatic steatosis have reported an attenuated effect of glucagon on glucose production thereby possibly linking pathophysiological traits of the liver to glucagon resistance [106,107]. Preliminary data from our group did, however, not support the notion of glucagon resistance with respect to its ability to stimulate hepatic glucose production in humans, but in contrast revealed an impaired effect on amino acid metabolism [108].

As alluded to above, it is poorly understood how glucagon secretion is suppressed during hyperglycemia [109–112]. In studies examining the effect of carbohydrates on glucagon secretion, glucagon secretion decreases in response to these stimuli, thereby deeming glucagon redundant for glucose homeostasis during these conditions [113,114]. (Orally administered glucose has, however, been reported to increase plasma concentrations of glucagon in healthy subjects and in patients with type 2 diabetes [115]). This is, however, not the case when high-fat or protein-rich meals are orally administered, as these stimuli increase glucagon secretion [113,116]. In a recent study of the importance of glucagon as a postprandial hormone in healthy individuals, oral administration of whey protein increased both endogenous glucose production and glucose disposal to the same degree [116]. Despite protein ingestion resulting in a concomitant increase in insulin and glucagon concentrations in the blood, euglycemia was preserved throughout the trial [116]. These data suggest that glucagon may be important for glucose flux during the postprandial state after protein ingestion.

A known characteristic of patients with type 2 diabetes is dysregulated glucagon secretion and many have consequently focused on glucagon antagonism [117,118]. Genetic and pharmacologic inhibition of glucagon signaling leads to lowering of fasting plasma glucose concentrations by approximately 1–2 mmol/L in mice and in humans [11,119–122]. These observations are in line with the early suggestion by Unger and colleagues that increased glucagon signaling is diabetogenic [123,124]. However, administration of a glucagon receptor antagonist (GRA) does not seem to affect postprandial glucose excursions in patients with type 2 diabetes [11], indicating that glucagon is important for glucose homeostasis in the fasting state rather than postprandially. GRAs are currently being pursued as a possible therapeutic target for the treatment of diabetes, though clinical data regarding different antagonists also comprise side effects including increases in liver fat, blood pressure, and low-density lipoprotein (LDL) cholesterol [125]. On the other hand, glucagon agonism has also been suggested as a potential therapeutic strategy for diabetes treatment due to its potential effect on appetite and insulin secretion [126]. Furthermore, co-infusion of glucagon and GLP-1 in overweight humans did not induce hyperglycemia or glucose intolerance but led to a greater decrease in food intake compared to that seen with GLP-1 alone [127]. Additionally, acute glucagon agonism in rodents shows improved glucose tolerance and improved glucose-stimulated insulin secretion after initial glucagon-induced hyperglycemia [126]. These data point to a more complicated interplay between peptide hormones



in the regulation of glucose homeostasis than hitherto thought, and several therapeutic strategies involving glucagon signaling are currently being investigated for diabetes treatment. A recent study from our group focused on the pharmacological effects of GRA on postprandial blood glucose in combinatory effect with an insulin receptor antagonist (IRA) [100]. During administration of both GRA and IRA, mice displayed blood glucose responses to a glucose challenge comparable to the vehicle group whereas (and as expected) the blood glucose response to the same challenge was higher after IRA only and lower after GRA only. This further supports the notion that for appropriate glucose homeostasis, both hormones are important [82].

There is no doubt that glucagon is important for the maintenance of normal glucose levels in humans [4]. However, studies carried out during the last decades suggest that glucagon is also a key regulator of hepatic amino acid metabolism, which, as discussed in the following Section, may be linked with hepatic steatosis/fibrosis and potentially dispose towards the development of type 2 diabetes [7].

### 5.2. Glucagon and Amino Acid Metabolism


Glucagon is a powerful stimulus for hepatic amino acid turnover [128,129] by induction of increased activity of enzymes in the urea cycle [130]. Through cAMP-PKA-CREB protein-mediated effects, glucagon regulates several enzymes in the urea cycle at a transcriptional level [129,131]. This is important considering that the capacity of ureagenesis is determined by enzyme activity [130], and long-term regulation of ureagenesis depends on the synthesis rate of the five necessary enzymes (shown in Figure 4). Glucagon also activates the transcription of system A amino acid transporters present in the hepatocyte membrane, thus allowing increased amino acid uptake and substrate availability for ureagenesis [132]. Thus, because ureagenesis is a substrate-regulated pathway, glucagon further induces ureagenesis by providing substrates via increased amino acid uptake. For short-term regulation of ureagenesis, acute activation of at least one of the five enzymes is necessary. *N*-acetyl glutamate (NAG) is the obligatory allosteric activator of carbamoyl phosphate synthetase-1 (CPS-1), and NAG formation, by *N*-acetyl glutamate synthetase (NAGS), is therefore an important factor for short-term regulation of the urea cycle. Steady-state levels of NAG are determined by glutamate and acetyl-CoA concentrations (the substrates for NAG), and activators of NAGS [133]. Glucagon regulates the transcription of NAGS [134], but the rapid increase in NAG concentration induced by glucagon signaling allows rapid activation of CPS-1 and may thus regulate the urea cycle within minutes. Thus, glucagon may acutely regulate hepatic amino acid metabolism via increased ureagenesis [5,128,135–139], and upon pharmacological blockade of glucagon receptor signaling, using a GRA, plasma concentrations of amino acids increase and ureagenesis decrease [135,137,140]. In accordance with this, inhibition of glucagon signaling also reduces the expression of genes involved in hepatic amino acid uptake and metabolism [121,141,142], resulting in hyperaminoacidemia [100,135,140,143]. The rapid changes in urea production upon glucagon signaling cannot be explained by transcriptional changes, and suggest that glucagon also allosterically activates the urea cycle; however, further studies are needed to clarify such a mechanism that may include acetylation [144], phosphorylation [145], sirtuins [146], and/or increased activity of amino acid transporters [121,147]. A detailed map covering the molecular mechanisms of how glucagon receptor signaling may lead to increased hepatic amino acid metabolism remains to be generated.

Secretion of glucagon is powerfully and rapidly stimulated by protein-containing meals [94,148]. Thus, glucagon may serve to regulate postprandial amino acid metabolism in accordance with its acute effect on amino acid metabolism. Postprandial insulin secretion during intake of protein-rich meals also needs to be taken into consideration. Conventionally, the secretion of insulin and glucagon is viewed as being inversely regulated, which is consistent with the opposite effects of the hormones on glucose metabolism. This is, however, not the case upon protein ingestion, as the secretion of both insulin and glucagon increase in response to amino acids [114,116]. To exemplify this further, consider two situations: If only carbohydrates are ingested, plasma concentrations of glucagon will drop in

healthy individuals, reaching values close to zero (or to the detection limits of the glucagon assay applied), whereas protein-rich meals are associated with marked increases in glucagon secretion. In the latter situation, the glucagon response is thought to compensate for the potential hypoglycemia induced by an amino acid-driven insulin secretion. However, both mechanisms may also serve to limit amino acid excursions; insulin, by increasing tissue uptake and deposition of amino acids in newly synthesized proteins, and glucagon, by enhancing amino acid metabolism [116,149] (whereas the glucagon receptor is not expressed on human skeletal muscle cells, precluding direct actions of glucagon). In the aforementioned study using both GRA and IRA administration in mice during intravenous administration of amino acids, only glucagon antagonism increased plasma amino acid concentrations compared to vehicle-treated controls, whereas insulin antagonism did not [100]. These findings indicate that clearance of amino acids during the postprandial state depends relatively more on glucagon receptor signaling than on insulin. Whether this also holds true in humans, we do not yet know.

Studies involving genetic or pharmacological ablation of glucagon receptor signaling in rodents are consistently associated with hyperglucagonemia, hyperaminoacidemia, and alpha cell hyperplasia [121,135,150]. In fact, both global and liver-specific elimination of glucagon receptor signaling in mice induces alpha cell hyperplasia. It is especially interesting that hepatic elimination of the glucagon receptor is sufficient to induce an increased alpha cell mass [150], pointing to a direct or indirect signaling loop between the liver and the pancreas. As previously stated, glucagon regulates amino acid metabolism via increased ureagenesis, and when glucagon signaling is inhibited, hyperaminoacidemia occurs. Hyperaminoacidemia is therefore suggested as the factor leading to alpha cell hyperplasia [121,135,141]. This endocrine feedback loop, in which glucagon induces hepatic amino acid metabolism and amino acids in turn stimulate glucagon secretion, has been named the liver–alpha cell axis [7,18]. The glucagonotropic amino acids, alanine and glutamine, may be of particular importance in this feedback loop in mediating alpha cell secretion and growth, respectively [142]. Glucagon receptor blockade also increases the expression of several amino acid transporters in the plasma membrane of alpha cells [121]. Upon pharmacological inhibition of glucagon receptor signaling the pancreatic expression of the amino acid transporter, Slc38a5, increased, and in mice deficient of this amino acid transporter, the development of alpha cell hyperplasia was prevented [121]. These findings did, however, not translate into human islets implanted into mice despite an observed alpha cell proliferation following pharmacological glucagon receptor inhibition [121]. Rather, glucagon receptor inhibition in mice with implanted human islets elicited an increased pancreatic expression of the amino acid transporter Slc38a4 [151]. When investigating molecular mechanisms responsible for increasing alpha cell mass in both rodents and implanted human islets after glucagon receptor blockade, the mechanistic target of the rapamycin (mTOR) pathway has been suggested to be involved [121,151]. However, this is a relatively broad signaling cascade involved in multiple cellular functions including mitosis, and therefore it is of interest to search for potential, more specific downstream targets of amino acid induced alpha cell proliferation.

The aforementioned observations of hyperaminoacidemia, alpha cell hyperplasia, and hyperglucagonemia mimic the manifestations of some metabolic diseases. Both alpha and beta cell proliferation may be increased in islets from patients with recent-onset type 1 diabetes [152]. Furthermore, some, but not all, subjects with type 2 diabetes show elevated glucagon concentrations in the fasting state and sometimes fail to suppress postprandial glucagon secretion [124,153,154]. The idea that not all type 2 diabetes patients display hyperglucagonemia was further nourished when type 2 diabetic patients were compared to patients with non-alcoholic fatty liver disease (NAFLD) [155], showing that NAFLD rather than diabetes was associated with hyperglucagonemia and hyperaminoacidemia [156].




**Figure 4.** Glucagon's effect on hepatic amino acid metabolism and ureagenesis. In the hepatocytes, transaminases catalyze the cleavage of the amino group in the form of ammonia, leaving behind the alpha-keto-acid of the respective amino acid. The amino group is transferred to  $\alpha$ -ketoglutarate, yielding glutamate. In addition, glutamine is transported via the circulation to the hepatocytes where glutaminase converts glutamine to glutamate and ammonium, which is deposited in the hepatocyte mitochondria. Alanine aminotransferase transfers the amino group from alanine to  $\alpha$ -ketoglutarate forming glutamate and leaving pyruvate behind. Glutamate enters the mitochondria of the hepatocyte where glutamate dehydrogenase catalyzes the cleavage of the amino group yielding ammonia and  $\alpha$ -ketoglutarate. The ammonia enters the urea cycle by conversion to carbamoyl phosphate, catalyzed by carbamoyl phosphate synthase-1 (CPS-1). Aspartate aminotransferase catalyzes the formation of aspartate via transamination of oxaloacetate and glutamate. Aspartate thus functions as the second nitrogen donor in the urea cycle. The urea cycle starts with N-acetyl-L-glutamate (NAG) formation, which is catalyzed by N-acetyl glutamate synthase (NAGS). NAG activates CPS-1, which catalyzes the formation of ammonia to carbamoyl phosphate. To form citrulline, the carbamoyl group is transferred from carbamoyl phosphate to ornithine, which is catalyzed by ornithine transcarbamylase. The next step requires argininosuccinate synthase and argininosuccinase, which convert citrulline and aspartate to argininosuccinate and subsequently to arginine and fumarate. Urea is then produced when arginase cleaves arginine. Glucagon receptor signaling increases urea cycle activity by activating the cAMP-protein kinase A (PKA)-cAMP response element-binding (CREB) protein-pathway, resulting in transcription of urea cycle enzymes and amino acid transporters, the latter serving to increase substrate availability. Glucagon may also allosterically activate the urea cycle by additional PKA mediated phosphorylations (see text).

That glucagon is a powerful regulator of amino acid metabolism further becomes evident in cases of extreme glucagon excess and deficiency [41]. Extreme hyperglucagonemia, as observed in patients with glucagon-producing tumors (glucagonomas), is associated with accelerated hepatic amino acid turnover and ureagenesis [90,157,158], resulting in severe hypoaminoacidemia [41,159–161] and increased plasma concentrations of urea [143,162]. In studies of the plasma metabolome [163] and proteome [164], the major

changes associated with glucagonomas are low levels of plasma amino acids. Glucagonomas are not, as a rule, linked to disturbed glucose metabolism; instead, patients often develop necrolytic migratory erythema, a skin disease associated with severe hypoaminoacidemia [165], which resolves upon intravenous infusions of amino acid [160,166]. Patients with inactivating glucagon receptor mutations (pseudohypoglucagonemia) show hyperaminoacidemia and hyperglucagonemia [167,168] and do not develop severe hypoglycemia. Likewise, pancreatectomized humans show hyperaminoacidemia, which can be normalized by glucagon administration [169]. Collectively, this suggests that one dominant effect of glucagon signaling is both acute (normally postprandial) and chronic regulation of amino acid metabolism; the two may be differentially regulated, and the involved mechanisms, as discussed above, need further exploration.

### 5.3. Glucagon and Lipid Metabolism

The glucagon receptor has, as discussed above, been considered a target for glucose-lowering therapy in type 2 diabetic patients. However, in a phase 2 clinical trial of GRAs (e.g., LY2409021), clinical concerns were raised. Despite the ability of a GRA to effectively lower blood glucose, blocking the glucagon receptor resulted in negative effects on lipid-related processes—the GRA-treated patients had higher total cholesterol, increased hepatic fat fraction (measured by magnetic resonance imaging), and weight gain as compared to controls [16]. Therefore, questions have been raised regarding the relationship between glucagon signaling and lipid metabolism (Figure 5).



**Figure 5.** Glucagon effect on lipid metabolism. Activation of the glucagon receptor results in adenylate cyclase-mediated cAMP formation. cAMP accumulation activates cAMP-responsive-binding-protein (CREB), inducing transcription of carnitine acyl transferase-1 (CPT-1) and other genes required for beta-oxidation. CPT-1 promotes conversion of fatty acids to acylcarnitines, which are transported into the mitochondria and broken down to acetate. Acetate and CoA react to form acetyl-CoA, which enters the citric acid cycle. cAMP accumulation activates protein kinase A (PKA), which leads to inactivation of acetyl-CoA carboxylase and thus suppression of malonyl-CoA formation and a disinhibition of beta-oxidation. Thus, glucagon promotes increased beta-oxidation and a decreased fatty acid synthesis and, in turn, very-low-density lipoprotein (VLDL) release.

Glucagon is known to act mainly on the hepatocytes, which is in line with the fact that the expression levels of glucagon receptors are highest in the liver. Adipocyte expression of the glucagon receptor is possible, but the expression seems to be restricted to rats rather than humans. Therefore, glucagon may primarily regulate lipid metabolism via hepatic signaling. This may involve the

following mechanisms. Firstly, when glucagon binds to its receptor on the hepatocyte, it activates cAMP, which in turn accumulates and activates CREB protein. As a consequence, transcription of carnitine acyl transferase (CPT-1) is increased, which enables conversion of fatty acids to acylcarnitines whereby beta-oxidation is activated [93], resulting in the formation of acetate [170,171]. Acetate and CoA react to yield acetyl-coA, which in turn interacts with oxaloacetate to form citrate (thereby inhibiting glycolysis), which enters the citric acid cycle [172]. As a result, hepatic glucagon signaling increases fatty acid catabolism, inhibits glycolysis, and stimulates the citric acid cycle. Secondly, when glucagon binds to its receptor on the hepatocyte, it induces PKA-dependent phosphorylation, which leads to inactivation of acetyl-CoA carboxylase, which functions to catalyze the formation of malonyl-CoA. Because malonyl-CoA is responsible for inhibiting CPT-1, and thus beta-oxidation, lowering malonyl-CoA levels results in a diversion of FFAs to beta-oxidation rather than re-esterification to triglycerols (TGs). Typically, when FFAs are re-esterified, they are stored as TGs and released from hepatocytes into circulation as very-low-density lipoprotein (VLDL). Taken together, glucagon decreases de novo fatty acid synthesis and, consequentially, VLDL release. Lastly, it is possible that glucagon signaling increases the AMP/ATP ratio necessary to activate AMP-activated kinase [173]. This leads to transcriptional activation of peroxisome proliferator-activated receptor- $\alpha$  [2], which induces transcription of beta-oxidation related genes such as CPT-1 and acetyl-CoA oxidase [174,175].

There is additionally in vivo support of the role of glucagon in hepatic lipid metabolism [176]. When mice were administered 30  $\mu\text{g/kg}$  of glucagon acutely, this resulted in decreased FFA and TG plasma concentrations as well as reduced hepatic TG content and secretion. Furthermore, an injection of 10  $\mu\text{g}$  of glucagon every eighth hour for 21 days resulted in a 70% and 38% decrease in plasma concentrations of TG and phospholipids, respectively [177]. In further support of this, synthesis and release of TG were inhibited by glucagon in cultured hepatocytes and in isolated hepatocytes [178,179]. Glucagon also decreased hepatic VLDL synthesis in rats [180]. In humans, hyperglucagonemia (during a pancreatic clamp) resulted in reduced hepatic lipoprotein particle turnover [181], and there has also been indications of a glucagon-mediated increase in hepatic beta-oxidation [182].

In addition to the clinical trials, which demonstrated negative effects on lipid metabolism by GRA administration in humans, similar results have been observed in rodent in vivo studies. In both rats [183] and diabetic (db/db) mice [184], treatment with a glucagon antisense oligonucleotide (impairing glucagon signaling) resulted in increased amounts of hepatic fat. In the livers of global glucagon receptor knockout ( $Gcgr^{-/-}$ ) mice, decreased gluconeogenesis and citric acid cycle activity, as well as increased glycolysis, was observed, potentially leading to increased hepatic lipogenesis due to decreased acetyl-CoA oxidation and accumulation. This is supported by reports of upregulation of genes involved in lipogenesis [93,185] and downregulation of enzymes involved in beta-oxidation (e.g., CPT-1) [185]. With regards to the development of steatosis in  $Gcgr^{-/-}$  mice, there are conflicting results [93,186]. When administered a glucagon/GLP-1 receptor co-agonist, type 2 diabetic and obese rodents displayed reduced hepatic steatosis, increased hormone-sensitive lipase (HSL) activity in adipocytes, and improved dyslipidemia [187–193]. The inhibitory effect on hepatic lipogenesis and the stimulatory effect on beta-oxidation would seem to be mediated particularly by glucagon receptor signaling rather than GLP-1-mediated effects [187,188]. As a result, a number of clinical studies are evaluating the potential for glucagon/GLP-1 receptor co-agonists for obesity and type 2 diabetes treatment [9].

One final aspect regarding the relationship between glucagon signaling and lipid metabolism is the effect in adipocytes. In adipocytes, lipolysis depends on PKA-dependent phosphorylation of HSL [194–196] and perilipins, which are present on the surface of lipid droplets [197]. Upon phosphorylation of perilipins, the protein CGI-58 dissociates, which in turn activates adipose triglycerol lipase, which is responsible for converting TGs to diacylglycerols. Additionally, phosphorylated perilipins bind HSL and allow it to access the area of the lipid droplet where diacylglycerols are converted to monoglycerols. Monoglycerol lipase hydrolyzes the monoglycerols, resulting in FFAs [198–202] and glycerol, which are released into the circulation. Circulating FFAs and glycerol levels are therefore



sensitive indicators of the rate of lipolysis [203]. In rat adipocytes, glucagon receptor mRNA has been detected [204,205], supporting an effect of glucagon on HSL [206,207] and subsequently lipolysis in rat adipocytes [208–214]. Despite this evidence in rats, there is no clear evidence of expression of a glucagon receptor on human adipocytes, and a lipolytic effect of glucagon at physiological plasma concentrations has been difficult to observe in humans [181,215–221]. Lipolytic responses to supra-physiological glucagon concentrations have been reported in humans (some resulting in concentrations upwards of >1000 pM) [222,223]. However, this is possibly a result of glucagon-stimulated secretion of catecholamines [224]. The lipolytic effect of supra-physiological glucagon concentration was abolished by insulin in some studies [222,223,225–227], and this is consistent with the powerful anti-lipolytic effects of insulin, also found in humans [208,209,225,228,229]. Therefore, if any such lipolytic effect of glucagon on human adipocytes exists, it is only of physiological interest during low insulin secretion [220,228,230].

## 6. Glucagon Resistance and Potential Biomarkers

Does glucagon resistance exist and is it measurable? We hypothesize that glucagon resistance is a molecular phenomenon characterizing impaired physiological effects of glucagon on glucose, amino acid and/or lipid metabolism, which for each of the three listed systems may occur independently. It is important to stress that the hypothesis is new and rests on relatively few observations with limited number of participants. That said, we believe it is important to discuss glucagon resistance as it may aid our understanding of glucagon biology and its contribution to metabolic diseases and potentially allow us to understand the current challenges with glucagon agonism/antagonism by designing targeted therapies like, for example., glucagon-induced hepatic glucose production without tampering with its effect on amino acid and lipid metabolism.

Obesity (and malnutrition) has been suggested as a potential inducer of glucagon resistance in animal models [106,107,231,232], but to what extent this is recapitulated in humans is not yet clear. One study in humans with biopsy-verified hepatic steatosis was presented in 2018 at the American Diabetes Association Scientific Session, reporting that fat infiltration may cause glucagon resistance regarding amino acid metabolism whereas the acute effect of glucagon on hepatic glucose production was preserved [108]. This observation would be in agreement with findings of an attenuated capacity for ureagenesis in individuals with hepatic steatosis [233,234]. One explanation may be that impaired liver function/structure directly affects the transcription of enzymes related to ureagenesis such as CPS-1 or that the effect of glucagon receptor signaling on the same components is impaired. In support of the latter, glucagon receptor knockout (be it liver specific or not) alters the hepatic transcriptome including lowered levels of ureagenesis-related transcripts [7,142,235]. A key regulator of gluconeogenesis is substrate availability, as discussed earlier, and not primarily hormonal systems (insulin and glucagon), whereas ureagenesis may be more dependent on hormonal regulation (but obviously still dependent on a certain flux of substrates) [5,128,138,140]. It will therefore be important to dissect the molecular signals that separate gluconeogenesis from ureagenesis and how these are affected by glucagon receptor signaling. Protein kinase c has been suggested as a potential mediator of glucagon receptor desensitization (measured as impaired production of cAMP, the second-messenger of glucagon receptor activation) [236]. Glucagon receptor internalization [237–239] may be a potential mechanism driving glucagon resistance, although others have found glucagon receptor internalization to be minimal compared to, e.g., insulin receptor internalization. It has also been suggested that lipids may interfere with glucagon receptor signaling [81,240] (a case for glucagon resistance was made using adipocytes, relevant for rats [212]). We believe that an important step is to differentiate between chronic (changing protein levels of, e.g., CPS-1) and acute effects of glucagon (e.g., phosphorylation of NAG)—both requires studies examining unbiased changes in the proteome and post-translational modifications, respectively. Further evidence is clearly required to pinpoint impaired glucagon receptor signaling.

How can glucagon resistance be measured and thereby further investigated? In analogy with hepatic insulin resistance, it would be logical to look at effector (insulin/C-peptide) and outcome (glucose)



concentrations in plasma. Here, the corresponding parameters would be plasma concentrations of glucagon and amino acids. As discussed above, insulin concentrations might also be considered.

Both measures are sensitive to the accuracy of the measurement methodologies applied (e.g., cross-reactivity to other proglucagon-derived peptides may create false-positive hyperglucagonemia). In addition glucagon levels may be dependent on intact renal function (hyperglucagonemia in patients with renal disease may be composed of not only 1–29 glucagon but also considerable amount of 1–61 [79]). The glucagon/insulin ratio may, on the other hand, be affected by insulin resistance (be it hepatic or peripheral), resulting in increased beta cell secretion (that eventually will fall in line with beta cell failure) and may be invalid in the cases exogenous insulin (late stage type 2 diabetes or type 1 diabetes). That said, to evaluate glucagon's impact on, for example, glucose production in individuals with and without hepatic steatosis, the manipulation of the glucagon/insulin ratio by somatostatin-induced pancreas clamps and continuous infusion of insulin and glucagon may be a tool to investigate glucagon resistance [241]. Therefore, we speculate that plasma concentrations of glucagon, preferably measured by accurate sandwich ELISA techniques [77], are the golden standard to assess existence of hyperglucagonemia [81] and hence potentially also glucagon resistance. Two recent studies from our group have found support of a glucagon-alanine index that captures the lack of glucagon-induced ureagenesis [155,156], which seems to be specifically impaired in patients with hepatic steatosis and fibrosis [233,234]. Of note, alanine is also involved in the alanine-glucose shuttle between the skeletal muscle and the liver, enabling substrate flow to hepatic gluconeogenesis, and given that glucagon receptor signaling is lacking in skeletal muscle cells (as they do not express the glucagon receptor), the proposed index may therefore reflect the liver–alpha cell axis rather than a muscle–liver–alpha cell axis. However, this will need independent validation by other research groups and larger cohorts (although the index was formed on the basis of results from >1400 individuals).

## 7. Outlook and Conclusions

In this review, we have discussed the essential aspects of glucagon biology with an emphasis on glucagon resistance as a new, potential physiological concept. We provide an overview of the three major biological areas of glucagon receptor signaling: glucose homeostasis, amino acid metabolism, and lipid metabolism. The two latter areas are not as well characterized as the former, and future mechanistic studies involving glucagon agonism/antagonism may be helpful to delineate the physiological importance of glucagon in these areas. Key physiological questions remain unanswered: Are all amino acids affected by glucagon receptor signaling or is it only those with glucagonotropic effects? Does glucagon have a physiological effect on lipid metabolism in humans? The concept of glucagon resistance must be further investigated before conclusions about its relevance in metabolic diseases can be reached. Nevertheless, further studies of the concept will be useful and important for our understanding of glucagon pathobiology.

Research during the coming years may provide answers to whether or not glucagon agonism/antagonism will reach clinical application for treatment of metabolic diseases such as obesity and type 2 diabetes [9]. Interestingly, glucagon agonism (low-dose glucagon) is likely to be applied together with insulin in the dual pump systems development for type 1 diabetes therapy [242]. Furthermore, as glucagon receptor antagonism may result in dyslipidemia, hyperaminoacidemia and hepatic lipid deposition, it has been suggested that glucagon agonism may be of therapeutic relevance for treatment of type 2 diabetes [243]. Future studies will tell whether this holds true, but it seems evident that targeting glucagon receptor signaling alone may be inappropriate because of possible worsening of glycemic control, but perhaps either biased glucagon receptor signaling or glucagon agonism in combination with another therapeutic agent (e.g., GLP-1) may solve this problem.

Thus, glucagon biology remains a challenging but an exciting research object [6].

**Funding:** NNF Tandem Programme (31526), NNF Project support in Endocrinology and Metabolism—Nordic Region (34250), and Excellence Emerging Investigator Grant—Endocrinology and Metabolism (NNF19OC0055001).

**Acknowledgments:** We appreciate the discussions on this topic with Liselotte Gluud and Kirstine Bojsen-Møller (Hvidovre Hospital, Hvidovre, Denmark).

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

## Abbreviations

CPS-1	carbamyl phosphate synthetase-1
CPT-1	carnitine acyl transferase-1
CREB	cAMP response element-binding
FBPase2	Fructose 2,6-bisphosphatase
FFA	Free fatty acid
Gcgr <sup>-/-</sup>	Glucagon receptor knockout
GLP-1	Glucagon-like peptide-1
GLP-2	Glucagon-like peptide-2
GIP	Glucose-dependent insulintropic polypeptide
GRA	Glucagon receptor antagonist
HCD	High carbohydrate diet
HSL	Hormone sensitive lipase
IRA	Insulin receptor antagonist
LCD	Low carbohydrate diet
LDL	Low density lipoprotein
NAFLD	Non alcoholic fatty liver disease
NAG	N-acetyl glutamate
NAGS	N-acetyl glutamate synthetase
PEPCK	Phosphoenolpyruvatecarboxykinase
PFK-2	Phospho-fructokinase 2
PKA	Protein kinase A
TG	Triglyceride
VLDL	Very-low density lipoprotein

## References

1. Scott, R.V.; Bloom, S.R. Problem or solution: The strange story of glucagon. *Peptides* **2018**, *100*, 36–41. [[CrossRef](#)] [[PubMed](#)]
2. Kimball, C.P.; Murlin, J.R. Aqueous Extracts of Pancreas: III. Some Precipitation Reactions of Insulin. *J. Biol. Chem.* **1923**, *58*, 337–346.
3. Sutherland, E.W.; Cori, C.F.; Haynes, R.; Olsen, N.S. Purification of the hyperglycemic-glycogenolytic factor from insulin and from gastric mucosa. *J. Biol. Chem.* **1949**, *180*, 825–837. [[PubMed](#)]
4. Muller, T.D.; Finan, B.; Clemmensen, C.; DiMarchi, R.D.; Tschop, M.H. The New Biology and Pharmacology of Glucagon. *Physiol. Rev.* **2017**, *97*, 721–766. [[CrossRef](#)] [[PubMed](#)]
5. Vilstrup, H.; Hansen, B.A.; Almdal, T.P. Glucagon increases hepatic efficacy for urea synthesis. *J. Hepatol.* **1990**, *10*, 46–50. [[CrossRef](#)]
6. Gromada, J.; Franklin, I.; Wollheim, C.B.  $\alpha$ -Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains. *Endocr. Rev.* **2007**, *28*, 84–116. [[CrossRef](#)] [[PubMed](#)]
7. Wewer Albrechtsen, N.J.; Pedersen, J.; Galsgaard, K.D.; Winther-Sorensen, M.; Suppli, M.P.; Janah, L.; Gromada, J.; Vilstrup, H.; Knop, F.K.; Holst, J.J. The liver-alpha cell axis and type 2 diabetes. *Endocr. Rev.* **2019**. [[CrossRef](#)]
8. Pearson, M.J.; Unger, R.H.; Holland, W.L. Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists. *Diabetes Care* **2016**, *39*, 1075–1077. [[CrossRef](#)]
9. Capozzi, M.E.; DiMarchi, R.D.; Tschop, M.H.; Finan, B.; Campbell, J.E. Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes. *Endocr. Rev.* **2018**, *39*, 719–738. [[CrossRef](#)]

10. Ambery, P.; Parker, V.E.; Stumvoll, M.; Posch, M.G.; Heise, T.; Plum-Moerschel, L.; Tsai, L.-F.; Robertson, D.; Jain, M.; Petrone, M.; et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: A randomised, controlled, double-blind, ascending dose and phase 2a study. *Lancet* **2018**, *391*, 2607–2618. [[CrossRef](#)]
11. Kazda, C.M.; Ding, Y.; Kelly, R.P.; Garhyan, P.; Shi, C.; Lim, C.N.; Fu, H.; Watson, D.E.; Lewin, A.J.; Landschulz, W.H.; et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients with Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. *Diabetes Care* **2016**, *39*, 1241–1249. [[CrossRef](#)] [[PubMed](#)]
12. Raskin, P.; Unger, R.H. Hyperglucagonemia and Its Suppression. *N. Engl. J. Med.* **1978**, *299*, 433–436. [[CrossRef](#)] [[PubMed](#)]
13. Hare, K.J.; Vilsboll, T.; Holst, J.J.; Knop, F.K. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. *Am. J. Physiol. Endocrinol. Metab.* **2010**, *298*, E832–E837. [[CrossRef](#)] [[PubMed](#)]
14. Faerch, K.; Vistisen, D.; Pacini, G.; Torekov, S.S.; Johansen, N.B.; Witte, D.R.; Jonsson, A.; Pedersen, O.; Hansen, T.; Lauritzen, T.; et al. Insulin Resistance is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals with Normal and Impaired Glucose Regulation. *Diabetes* **2016**, *65*, 3473–3481. [[CrossRef](#)] [[PubMed](#)]
15. Cegla, J.; Jones, B.J.; Gardiner, J.V.; Hodson, D.J.; Marjot, T.; McGlone, E.R.; Tan, T.M.; Bloom, S.R. RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling. *Endocrinology* **2017**, *158*, 2680–2693. [[CrossRef](#)] [[PubMed](#)]
16. Guzman, C.B.; Zhang, X.M.; Liu, R.; Regev, A.; Shankar, S.; Garhyan, P.; Pillai, S.G.; Kazda, C.; Chalasani, N.; Hardy, T.A. Treatment with LY2409021, a Glucagon Receptor Antagonist, Increases Liver Fat in Patients with Type 2 Diabetes. *Diabetes Obes. Metab.* **2017**, *19*, 1521–1528. [[CrossRef](#)]
17. Bell, G.I.; Santerre, R.F.; Mullenbach, G.T. Hamster proglucagon contains the sequence of glucagon and two related peptides. *Nature* **1983**, *302*, 716–718. [[CrossRef](#)]
18. Wewer Albrechtsen, N.J. Glucagon receptor signaling in metabolic diseases. *Peptides* **2018**, *100*, 42–47. [[CrossRef](#)]
19. Steiner, D.F.; Wewer Albrechtsen, N.J.; Rehfeld, J.F.; Holst, J.J. Glucagon Processing. In *Reference Module in Neuroscience and Biobehavioral Psychology*; Elsevier: Amsterdam, The Netherlands, 2017.
20. Wewer Albrechtsen, N.J.; Kuhre, R.E.; Torang, S.; Holst, J.J. The intestinal distribution pattern of appetite-and glucose regulatory peptides in mice, rats and pigs. *BMC Res. Notes* **2016**, *9*, 60. [[CrossRef](#)]
21. Roberts, G.P.; Larraufie, P.; Richards, P.; Kay, R.G.; Galvin, S.G.; Miedzybrodzka, E.L.; Leiter, A.; Li, H.J.; Glass, L.L.; Ma, M.K.L.; et al. Comparison of Human and Murine Enteroendocrine Cells by Transcriptomic and Peptidomic Profiling. *Diabetes* **2019**, *68*, 1062–1072. [[CrossRef](#)]
22. Drucker, D.J.; Habener, J.F.; Holst, J.J. Discovery, characterization, and clinical development of the glucagon-like peptides. *J. Clin. Investig.* **2017**, *127*, 4217–4227. [[CrossRef](#)] [[PubMed](#)]
23. Drucker, D.J.; Yusta, B. Physiology and Pharmacology of the Enteroendocrine Hormone Glucagon-Like Peptide-2. *Annu. Rev. Physiol.* **2014**, *76*, 561–583. [[CrossRef](#)] [[PubMed](#)]
24. Estall, J.L.; Drucker, D.J. Glucagon and glucagon-like peptide receptors as drug targets. *Curr. Pharm. Des.* **2006**, *12*, 1731–1750. [[CrossRef](#)] [[PubMed](#)]
25. Chaudhri, O.B.; Field, B.C.; Bloom, S.R. Gastrointestinal satiety signals. *Int. J. Obes. (Lond.)* **2008**, *32*, S28–S31. [[CrossRef](#)] [[PubMed](#)]
26. Holst, J.J. The Physiology of Glucagon-like Peptide 1. *Physiol. Rev.* **2007**, *87*, 1409–1439. [[CrossRef](#)] [[PubMed](#)]
27. Mineo, I.; Matsumura, T.; Shingu, R.; Namba, M.; Kuwajima, M.; Matsuzawa, Y. The role of prohormone convertases PC1 (PC3) and PC2 in the cell-specific processing of proglucagon. *Biochem. Biophys. Res. Commun.* **1995**, *207*, 646–651. [[CrossRef](#)] [[PubMed](#)]
28. Rothenberg, M.E.; Eilertson, C.D.; Klein, K.; Zhou, Y.; Lindberg, I.; McDonald, J.K.; Mackin, R.B.; Noe, B.D. Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro. *J. Biol. Chem.* **1995**, *270*, 10136–10146. [[CrossRef](#)]
29. Dhanvantari, S.; Brubaker, P.L. Proglucagon processing in an islet cell line: Effects of PC1 overexpression and PC2 depletion. *Endocrinology* **1998**, *139*, 1630–1637. [[CrossRef](#)]
30. Ugleholdt, R.; Zhu, X.; Deacon, C.F.; Orskov, C.; Steiner, D.F.; Holst, J.J. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. *Endocrinology* **2004**, *145*, 1349–1355. [[CrossRef](#)]

31. Webb, G.C.; Dey, A.; Wang, J.; Stein, J.; Milewski, M.; Steiner, D.F. Altered proglucagon processing in an alpha-cell line derived from prohormone convertase 2 null mouse islets. *J. Biol. Chem.* **2004**, *279*, 31068–31075. [[CrossRef](#)]
32. Wideman, R.D.; Covey, S.D.; Webb, G.C.; Drucker, D.J.; Kieffer, T.J. A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice. *Diabetes* **2007**, *56*, 2744–2752. [[CrossRef](#)] [[PubMed](#)]
33. Thorens, B. Brain glucose sensing and neural regulation of insulin and glucagon secretion. *Diabetesobes. Metab.* **2011**, *13*, 82–88. [[CrossRef](#)] [[PubMed](#)]
34. Cherrington, A.; Vranic, M. Role of glucagon and insulin in control of glucose turnover. *Metabolism* **1971**, *20*, 625–628. [[CrossRef](#)]
35. Unger, R.H.; Ohneda, A.; Aguilar-Parada, E.; Eisentraut, A.M. The role of aminogenic glucagon secretion in blood glucose homeostasis. *J. Clin. Investig.* **1969**, *48*, 810–822. [[CrossRef](#)] [[PubMed](#)]
36. Gerich, J.E.; Langlois, M.; Schneider, V.; Karam, J.H.; Noacco, C. Effects of alternations of plasma free fatty acid levels on pancreatic glucagon secretion in man. *J. Clin. Investig.* **1974**, *53*, 1284–1289. [[CrossRef](#)] [[PubMed](#)]
37. Bloom, S.R.; Daniel, P.M.; Johnston, D.I.; Ogawa, O.; Pratt, O.E. Release of glucagon, induced by stress. *Q. J. Exp. Physiol. Cogn. Med. Sci.* **1973**, *58*, 99–108. [[CrossRef](#)] [[PubMed](#)]
38. Ashcroft, F.M.; Rorsman, P. K(ATP) channels and islet hormone secretion: New insights and controversies. *Nat. Rev. Endocrinol.* **2013**, *9*, 660–669. [[CrossRef](#)]
39. Gaisano, H.; MacDonald, P.; Vranic, M. Glucagon secretion and signaling in the development of diabetes. *Front. Physiol.* **2012**, *3*, 349. [[CrossRef](#)]
40. Rorsman, P.; Braun, M.; Zhang, Q. Regulation of calcium in pancreatic alpha- and beta-cells in health and disease. *Cell Calcium* **2012**, *51*, 300–308. [[CrossRef](#)]
41. Wewer Albrechtsen, N.J.; Kuhre, R.E.; Pedersen, J.; Knop, F.K.; Holst, J.J. The biology of glucagon and the consequences of hyperglucagonemia. *Biomark. Med.* **2016**, *10*, 1141–1151. [[CrossRef](#)]
42. Quesada, I.; Tuduri, E.; Ripoll, C.; Nadal, Á. Physiology of the pancreatic  $\alpha$ -cell and glucagon secretion: Role in glucose homeostasis and diabetes. *J. Endocrinol.* **2008**, *199*, 5–19. [[CrossRef](#)] [[PubMed](#)]
43. Campbell, J.E.; Drucker, D.J. Islet alpha cells and glucagon critical regulators of energy homeostasis. *Nat. Rev. Endocrinol.* **2015**, *11*, 329–338. [[CrossRef](#)] [[PubMed](#)]
44. Briant, L.; Salehi, A.; Vergari, E.; Zhang, Q.; Rorsman, P. Glucagon secretion from pancreatic  $\alpha$ -cells. *Uppsala J. Med. Sci.* **2016**, *121*, 113–119. [[CrossRef](#)] [[PubMed](#)]
45. Walker, J.N.; Ramracheya, R.; Zhang, Q.; Johnson, P.R.; Braun, M.; Rorsman, P. Regulation of glucagon secretion by glucose: Paracrine, intrinsic or both? *Diabetesobes. Metab.* **2011**, *13*, 95–105. [[CrossRef](#)] [[PubMed](#)]
46. Zhang, Q.; Ramracheya, R.; Lahmann, C.; Tarasov, A.; Bengtsson, M.; Braha, O.; Braun, M.; Brereton, M.; Collins, S.; Galvanovskis, J.; et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. *Cell Metab.* **2013**, *18*, 871–882. [[CrossRef](#)] [[PubMed](#)]
47. Hevener, A.L.; Bergman, R.N.; Donovan, C.M. Novel glucosensor for hypoglycemic detection localized to the portal vein. *Diabetes* **1997**, *46*, 1521–1525. [[CrossRef](#)] [[PubMed](#)]
48. Gerich, J.E.; Charles, M.A.; Grodsky, G.M. Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. *J. Clin. Investig.* **1974**, *54*, 833–841. [[CrossRef](#)]
49. Basco, D.; Zhang, Q.; Salehi, A.; Tarasov, A.; Dolci, W.; Herrera, P.; Spiliotis, I.; Berney, X.; Tarussio, D.; Rorsman, P.; et al.  $\alpha$ -cell glucokinase suppresses glucose-regulated glucagon secretion. *Nat. Commun.* **2018**, *9*, 546. [[CrossRef](#)]
50. Chakera, A.J.; Hurst, P.S.; Spyer, G.; Ogunnowo-Bada, E.O.; Marsh, W.J.; Riches, C.H.; Yueh, C.-Y.; Markkula, S.P.; Dalley, J.W.; Cox, R.D.; et al. Molecular Reductions in Glucokinase Activity Increase Counter-regulatory Responses to Hypoglycemia in Mice and Humans with Diabetes. *Mol. Metab.* **2018**, *17*, 17–27. [[CrossRef](#)]
51. Salehi, A.; Vieira, E.; Gylfe, E. Paradoxical Stimulation of Glucagon Secretion by High Glucose Concentrations. *Diabetes* **2006**, *55*, 2318–2323. [[CrossRef](#)]
52. Vergari, E.; Knudsen, J.G.; Ramracheya, R.; Salehi, A.; Zhang, Q.; Adam, J.; Asterholm, I.W.; Benrick, A.; Briant, L.J.B.; Chibalina, M.V.; et al. Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion. *Nat. Commun.* **2019**, *10*, 139. [[CrossRef](#)] [[PubMed](#)]

53. Lai, B.-K.; Chae, H.; Gómez-Ruiz, A.; Cheng, P.; Gallo, P.; Antoine, N.; Beauloye, C.; Jonas, J.-C.; Seghers, V.; Seino, S.; et al. Somatostatin is Only Partly Required for the Glucagonostatic Effect of Glucose but is Necessary for the Glucagonostatic Effect of K<sub>ATP</sub> Channel Blockers. *Diabetes* **2018**, *67*, 2239–2253. [[CrossRef](#)] [[PubMed](#)]
54. Van der Meulen, T.; Donaldson, C.J.; Cáceres, E.; Hunter, A.E.; Cowing-Zitron, C.; Pound, L.D.; Adams, M.W.; Zembrzycki, A.; Grove, K.L.; Huising, M.O. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. *Nat. Med.* **2015**, *21*, 769. [[CrossRef](#)] [[PubMed](#)]
55. Hardy, A.B.; Serino, A.S.; Wijesekara, N.; Chimienti, F.; Wheeler, M.B. Regulation of glucagon secretion by zinc: Lessons from the beta cell-specific Znt8 knockout mouse model. *Diabetesobes. Metab.* **2011**, *13*, 112–117. [[CrossRef](#)] [[PubMed](#)]
56. Cabrera, O.; Jacques-Silva, M.C.; Speier, S.; Yang, S.-N.; Köhler, M.; Fachado, A.; Vieira, E.; Zierath, J.R.; Kibbey, R.; Berman, D.M.; et al. Glutamate is a Positive Autocrine Signal for Glucagon Release. *Cell Metab.* **2008**, *7*, 545–554. [[CrossRef](#)] [[PubMed](#)]
57. Kawai, K.; Unger, R.H. Effects of gamma-aminobutyric acid on insulin, glucagon, and somatostatin release from isolated perfused dog pancreas. *Endocrinology* **1983**, *113*, 111–113. [[CrossRef](#)]
58. Gedulin, B.R.; Jodka, C.M.; Herrmann, K.; Young, A.A. Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187. *Regul. Pept.* **2006**, *137*, 121–127. [[CrossRef](#)]
59. Hutchens, T.; Piston, D.W. EphA4 Receptor Forward Signaling Inhibits Glucagon Secretion From  $\alpha$ -Cells. *Diabetes* **2015**, *64*, 3839–3851. [[CrossRef](#)]
60. Wettergren, A.; Schjoldager, B.; Mortensen, P.E.; Myhre, J.; Christiansen, J.; Holst, J.J. Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. *Dig. Dis. Sci.* **1993**, *38*, 665–673. [[CrossRef](#)]
61. Meier, J.J.; Gallwitz, B.; Siepmann, N.; Holst, J.J.; Deacon, C.F.; Schmidt, W.E.; Nauck, M.A. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. *Diabetologia* **2003**, *46*, 798–801. [[CrossRef](#)]
62. Meier, J.J.; Nauck, M.A.; Pott, A.; Heinze, K.; Goetze, O.; Bulut, K.; Schmidt, W.E.; Gallwitz, B.; Holst, J.J. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. *Gastroenterology* **2006**, *130*, 44–54. [[CrossRef](#)] [[PubMed](#)]
63. Salehi, A.; Dornonville de la Cour, C.; Hakanson, R.; Lundquist, I. Effects of ghrelin on insulin and glucagon secretion: A study of isolated pancreatic islets and intact mice. *Regul. Pept.* **2004**, *118*, 143–150. [[CrossRef](#)] [[PubMed](#)]
64. Unger, R.H.; Ketterer, H.; Dupré, J.; Eisentraut, A.M. The Effects of Secretin, Pancreozymin, and Gastrin on Insulin and Glucagon Secretion in Anesthetized Dogs. *J. Clin. Investig.* **1967**, *46*, 630–645. [[CrossRef](#)] [[PubMed](#)]
65. Ferrannini, E.; Muscelli, E.; Frascerra, S.; Baldi, S.; Mari, A.; Heise, T.; Broedl, U.C.; Woerle, H.-J. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. *J. Clin. Investig.* **2014**, *124*, 499–508. [[CrossRef](#)] [[PubMed](#)]
66. Merovci, A.; Solis-Herrera, C.; Daniele, G.; Eldor, R.; Fiorentino, T.V.; Tripathy, D.; Xiong, J.; Perez, Z.; Norton, L.; Abdul-Ghani, M.A.; et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. *J. Clin. Investig.* **2014**, *124*, 509–514. [[CrossRef](#)] [[PubMed](#)]
67. Bonner, C.; Kerr-Conte, J.; Gmyr, V.; Queniat, G.; Moerman, E.; Thevenet, J.; Beaucamps, C.; Delalleau, N.; Popescu, I.; Malaisse, W.J.; et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. *Nat. Med.* **2015**, *21*, 512–517. [[CrossRef](#)] [[PubMed](#)]
68. Solini, A.; Sebastiani, G.; Nigi, L.; Santini, E.; Rossi, C.; Dotta, F. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. *Diabetes Metab.* **2017**, *43*, 512–520. [[CrossRef](#)] [[PubMed](#)]
69. Kim, M.; Lee, E.J.; Shin, H.M.; Jung, H.S.; Kim, T.K.; Kim, T.N.; Kwon, M.J.; Lee, S.H.; Rhee, B.D.; Park, J.H. The effect of PPARgamma agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia. *J. Endocrinol. Investig.* **2017**, *40*, 1069–1076. [[CrossRef](#)] [[PubMed](#)]
70. Pedersen, M.G.; Ahlstedt, I.; El Hachmane, M.F.; Göpel, S.O. Dapagliflozin stimulates glucagon secretion at high glucose: Experiments and mathematical simulations of human A-cells. *Sci. Rep.* **2016**, *6*, 31214. [[CrossRef](#)]



71. Wang, M.-Y.; Yu, X.; Lee, Y.; McCorkle, S.K.; Chen, S.; Li, J.; Wang, Z.V.; Davidson, J.A.; Scherer, P.E.; Holland, W.L.; et al. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 6611–6616. [[CrossRef](#)]
72. Jurczak, M.J.; Lee, H.-Y.; Birkenfeld, A.L.; Jornayvaz, F.R.; Frederick, D.W.; Pongratz, R.L.; Zhao, X.; Moeckel, G.W.; Samuel, V.T.; Whaley, J.M.; et al. SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic  $\beta$ -Cell Function. *Diabetes* **2011**, *60*, 890–898. [[CrossRef](#)] [[PubMed](#)]
73. Cheng, S.T.W.; Chen, L.; Li, S.Y.T.; Mayoux, E.; Leung, P.S. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic  $\beta$ -Cell Mass and Glucose Homeostasis in Type 1 Diabetes. *PLoS ONE* **2016**, *11*, e0147391. [[CrossRef](#)] [[PubMed](#)]
74. Lundkvist, P.; Pereira, M.J.; Kamble, P.G.; Katsogiannos, P.; Langkilde, A.M.; Esterline, R.; Johnsson, E.; Eriksson, J.W. Glucagon Levels during Short-term SGLT2 Inhibition are Largely Regulated by Glucose Changes in Type 2 Diabetes Patients. *J. Clin. Endocrinol. Metab.* **2018**, *104*, 193–201. [[CrossRef](#)] [[PubMed](#)]
75. Kuhre, R.E.; Ghiasi, S.M.; Adriaenssens, A.E.; Wewer Albrechtsen, N.J.; Andersen, D.B.; Aivazidis, A.; Chen, L.; Mandrup-Poulsen, T.; Orskov, C.; Gribble, F.M.; et al. No direct effect of SGLT2 activity on glucagon secretion. *Diabetologia* **2019**, *62*, 1011–1023. [[CrossRef](#)] [[PubMed](#)]
76. Bak, M.J.; Albrechtsen, N.W.; Pedersen, J.; Hartmann, B.; Christensen, M.; Vilsbøll, T.; Knop, F.K.; Deacon, C.F.; Dragsted, L.O.; Holst, J.J. Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. *Eur. J. Endocrinol.* **2014**, *170*, 529–538. [[CrossRef](#)]
77. Albrechtsen, N.J.W. Measurement of Gastrointestinal Hormones. *Dan. Med. J.* **2017**, *64*, B5425.
78. Roberts, G.P.; Kay, R.G.; Howard, J.; Hardwick, R.H.; Reimann, F.; Gribble, F.M. Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery. *Surg. Obes. Relat. Dis. Off. J. Am. Soc. Bariat. Surg.* **2018**, *14*, 562–568. [[CrossRef](#)]
79. Wewer Albrechtsen, N.J.; Kuhre, R.E.; Hornburg, D.; Jensen, C.Z.; Hornum, M.; Dirksen, C.; Svane, M.; Gasbjerg, L.S.; Jorgensen, N.B.; Gabe, M.N.; et al. Circulating Glucagon 1–61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. *Cell Rep.* **2017**, *21*, 1452–1460. [[CrossRef](#)]
80. Baldissera, F.G.; Holst, J.J. Glicentin 1–61 probably represents a major fraction of glucagon-related peptides in plasma of anaesthetized uraemic pigs. *Diabetologia* **1986**, *29*, 462–467. [[CrossRef](#)]
81. Wewer Albrechtsen, N.; Hartmann, B.; Veedfald, S.; Windeløv, J.; Plamboeck, A.; Bojsen-Møller, K.; Idorn, T.; Feldt-Rasmussen, B.; Knop, F.; Vilsbøll, T.; et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: Nonspecific interference or truly elevated levels? *Diabetologia* **2014**, *57*, 1919–1926. [[CrossRef](#)]
82. Holst, J.J.; Holland, W.; Gromada, J.; Lee, Y.; Unger, R.H.; Yan, H.; Sloop, K.W.; Kieffer, T.J.; Damond, N.; Herrera, P.L. Insulin and Glucagon: Partners for Life. *Endocrinology* **2017**, *158*, 696–701. [[CrossRef](#)] [[PubMed](#)]
83. Ramnanan, C.J.; Edgerton, D.S.; Kraft, G.; Cherrington, A.D. Physiologic action of glucagon on liver glucose metabolism. *Diabetesobes. Metab.* **2011**, *13*, 118–125. [[CrossRef](#)] [[PubMed](#)]
84. Elrick, H.; Witten, T.A.; Arai, Y. Glucagon treatment of insulin reactions. *N. Engl. J. Med.* **1958**, *258*, 476–480. [[CrossRef](#)] [[PubMed](#)]
85. Reiband, H.K.; Schmidt, S.; Ranjan, A.; Holst, J.J.; Madsbad, S.; Norgaard, K. Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes. *Diabetes Metab. Res. Rev.* **2015**, *31*, 672–679. [[CrossRef](#)] [[PubMed](#)]
86. Jiang, G.; Zhang, B.B. Glucagon and regulation of glucose metabolism. *Am. J. Physiol. Endocrinol. Metab.* **2003**, *284*, E671–E678. [[CrossRef](#)]
87. Habegger, K.M.; Heppner, K.M.; Geary, N.; Bartness, T.J.; DiMarchi, R.; Tschop, M.H. The metabolic actions of glucagon revisited. *Nat. Rev. Endocrinol.* **2010**, *6*, 689–697. [[CrossRef](#)] [[PubMed](#)]
88. Cryer, P.E. Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes. *Endocrinology* **2012**, *153*, 1039–1048. [[CrossRef](#)] [[PubMed](#)]
89. Petersen, M.C.; Vatner, D.F.; Shulman, G.I. Regulation of hepatic glucose metabolism in health and disease. *Nat. Rev. Endocrinol.* **2017**, *13*, 572–587. [[CrossRef](#)] [[PubMed](#)]
90. Marliss, E.B.; Aoki, T.T.; Unger, R.H.; Soeldner, J.S.; Cahill, G.F., Jr. Glucagon levels and metabolic effects in fasting man. *J. Clin. Investig.* **1970**, *49*, 2256–2270. [[CrossRef](#)]
91. Brand, C.L.; Jorgensen, P.N.; Knigge, U.; Warberg, J.; Svendsen, I.; Kristensen, J.S.; Holst, J.J. Role of glucagon in maintenance of euglycemia in fed and fasted rats. *Am. J. Physiol.* **1995**, *269*, E469–E477. [[CrossRef](#)]



92. Brand, C.L.; Rolin, B.; Jorgensen, P.N.; Svendsen, I.; Kristensen, J.S.; Holst, J.J. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. *Diabetologia* **1994**, *37*, 985–993. [[CrossRef](#)] [[PubMed](#)]
93. Longuet, C.; Sinclair, E.M.; Maida, A.; Baggio, L.L.; Maziarz, M.; Charron, M.J.; Drucker, D.J. The glucagon receptor is required for the adaptive metabolic response to fasting. *Cell Metab.* **2008**, *8*, 359–371. [[CrossRef](#)] [[PubMed](#)]
94. Schmid, R.; Schusdziarra, V.; Schulte-Frohlinde, E.; Maier, V.; Classen, M. Role of amino acids in stimulation of postprandial insulin, glucagon, and pancreatic polypeptide in humans. *Pancreas* **1989**, *4*, 305–314. [[CrossRef](#)] [[PubMed](#)]
95. Unger, R.H. Glucagon physiology and pathophysiology. *N. Engl. J. Med.* **1971**, *285*, 443–449. [[CrossRef](#)] [[PubMed](#)]
96. Belanger, P.; Couturier, K.; Latour, M.G.; Lavoie, J.M. Effects of supranormal liver glycogen content on hyperglucagonemia-induced liver glycogen breakdown. *Eur. J. Appl. Physiol.* **2000**, *83*, 328–335. [[CrossRef](#)] [[PubMed](#)]
97. Ferrannini, E.; Mark, M.; Mayoux, E. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. *Diabetes Care* **2016**, *39*, 1108–1114. [[CrossRef](#)] [[PubMed](#)]
98. Mortensen, O.H.; Dichmann, D.S.; Abrahamsen, N.; Grunnet, N.; Nishimura, E. Identification of a novel human glucagon receptor promoter: Regulation by cAMP and PGC-1alpha. *Gene* **2007**, *393*, 127–136. [[CrossRef](#)]
99. Ranjan, A.; Schmidt, S.; Damm-Frydenberg, C.; Steineck, I.; Clausen, T.R.; Holst, J.J.; Madsbad, S.; Norgaard, K. Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study. *Diabetes Care* **2017**, *40*, 132–135. [[CrossRef](#)]
100. Galsgaard, K.D.; Winther-Sorensen, M.; Pedersen, J.; Kjeldsen, S.A.S.; Rosenkilde, M.M.; Wewer Albrechtsen, N.J.; Holst, J.J. Glucose and amino acid metabolism in mice depend mutually on glucagon and insulin receptor signaling. *Am. J. Physiol. Endocrinol. Metab.* **2019**, *316*, E660–E673. [[CrossRef](#)]
101. Ranjan, A.; Schmidt, S.; Madsbad, S.; Holst, J.J.; Norgaard, K. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes. *Diabetes Metab.* **2016**, *18*, 410–418. [[CrossRef](#)]
102. El Youssef, J.; Castle, J.R.; Bakhtiani, P.A.; Haidar, A.; Branigan, D.L.; Breen, M.; Ward, W.K. Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels. *Diabetes Care* **2014**, *37*, 3054–3060. [[CrossRef](#)] [[PubMed](#)]
103. Blauw, H.; Wendl, I.; DeVries, J.H.; Heise, T.; Jax, T. Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels. *Diabetes Metab.* **2016**, *18*, 34–39. [[CrossRef](#)] [[PubMed](#)]
104. Haymond, M.W.; Schreiner, B. Mini-Dose Glucagon Rescue for Hypoglycemia in Children with Type 1 Diabetes. *Diabetes Care* **2001**, *24*, 643. [[CrossRef](#)] [[PubMed](#)]
105. Hinshaw, L.; Mallad, A.; Dalla Man, C.; Basu, R.; Cobelli, C.; Carter, R.E.; Kudva, Y.C.; Basu, A. Glucagon sensitivity and clearance in type 1 diabetes: Insights from in vivo and in silico experiments. *Am. J. Physiol. Endocrinol. Metab.* **2015**, *309*, E474–E486. [[CrossRef](#)] [[PubMed](#)]
106. Charbonneau, A.; Couturier, K.; Gauthier, M.S.; Lavoie, J.M. Evidence of Hepatic Glucagon Resistance Associated with Hepatic Steatosis: Reversal Effect of Training. *Int. J. Sports Med.* **2005**, *26*, 432–441. [[CrossRef](#)] [[PubMed](#)]
107. Charbonneau, A.; Unson, C.G.; Lavoie, J.M. High-fat diet-induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: Potential interaction with acute exercise. *J. Physiol.* **2007**, *579*, 255–267. [[CrossRef](#)] [[PubMed](#)]
108. Suppli, M.P.; Bagger, J.I.; Lund, A.B.; Albrechtsen, N.J.W.; Holst, J.J.; Vilsbøll, T.; Knop, F.K. Glucagon Resistance at the Level of Amino Acid Turnover and Ureagenesis in Obese Subjects with Hepatic Steatosis. *Diabetes* **2018**, *67*. [[CrossRef](#)]
109. Gopel, S.O.; Kanno, T.; Barg, S.; Weng, X.G.; Gromada, J.; Rorsman, P. Regulation of glucagon release in mouse  $\alpha$ -cells by KATP channels and inactivation of TTX-sensitive Na<sup>+</sup> channels. *J. Physiol.* **2000**, *528*, 509–520. [[CrossRef](#)]
110. Ishihara, H.; Maechler, P.; Gjinovci, A.; Herrera, P.L.; Wollheim, C.B. Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. *Nat. Cell Biol.* **2003**, *5*, 330–335. [[CrossRef](#)]

111. Franklin, I.; Gromada, J.; Gjinovci, A.; Theander, S.; Wollheim, C.B. Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. *Diabetes* **2005**, *54*, 1808–1815. [[CrossRef](#)]
112. Olsen, H.L.; Theander, S.; Bokvist, K.; Buschard, K.; Wollheim, C.B.; Gromada, J. Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells. *Endocrinology* **2005**, *146*, 4861–4870. [[CrossRef](#)] [[PubMed](#)]
113. Kawai, K.; Murayama, Y.; Okuda, Y.; Yamashita, K. Postprandial glucose, insulin and glucagon responses to meals with different nutrient compositions in non-insulin-dependent diabetes mellitus. *Endocrinol. Jpn.* **1987**, *34*, 745–753. [[CrossRef](#)] [[PubMed](#)]
114. Muller, W.A.; Faloona, G.R.; Aguilar-Parada, E.; Unger, R.H. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. *N. Engl. J. Med.* **1970**, *283*, 109–115. [[CrossRef](#)] [[PubMed](#)]
115. Bagger, J.I.; Knop, F.K.; Lund, A.; Holst, J.J.; Vilsboll, T. Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. *Diabetologia* **2014**, *57*, 1720–1725. [[CrossRef](#)] [[PubMed](#)]
116. Ang, T.; Bruce, C.R.; Kowalski, G.M. Postprandial Aminogenic Insulin and Glucagon Secretion Can Stimulate Glucose Flux in Humans. *Diabetes* **2019**, *68*, 939–946. [[CrossRef](#)] [[PubMed](#)]
117. Bagger, J.I.; Knop, F.K.; Holst, J.J.; Vilsboll, T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. *Diabetes Obes. Metab.* **2011**, *13*, 965–971. [[CrossRef](#)]
118. Sloop, K.W.; Michael, M.D.; Moyers, J.S. Glucagon as a target for the treatment of Type 2 diabetes. *Expert Opin. Ther. Targets* **2005**, *9*, 593–600. [[CrossRef](#)]
119. Scheen, A.J.; Paquot, N.; Lefebvre, P.J. Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes. *Expert Opin. Investig. Drugs* **2017**, *26*, 1373–1389. [[CrossRef](#)]
120. Gelling, R.W.; Du, X.Q.; Dichmann, D.S.; Romer, J.; Huang, H.; Cui, L.; Obici, S.; Tang, B.; Holst, J.J.; Fledelius, C.; et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 1438–1443. [[CrossRef](#)]
121. Kim, J.; Okamoto, H.; Huang, Z.; Anguiano, G.; Chen, S.; Liu, Q.; Cavino, K.; Xin, Y.; Na, E.; Hamid, R.; et al. Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic alpha Cell Hyperplasia in Mice. *Cell Metab.* **2017**, *25*, 1348–1361. [[CrossRef](#)]
122. Sorensen, H.; Winzell, M.S.; Brand, C.L.; Fosgerau, K.; Gelling, R.W.; Nishimura, E.; Ahren, B. Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. *Diabetes* **2006**, *55*, 3463–3469. [[CrossRef](#)] [[PubMed](#)]
123. Unger, R.H.; Cherrington, A.D. Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. *J. Clin. Investig.* **2012**, *122*, 4–12. [[CrossRef](#)] [[PubMed](#)]
124. Unger, R.H.; Aguilar-Parada, E.; Müller, W.A.; Eisentraut, A.M. Studies of pancreatic alpha cell function in normal and diabetic subjects. *J. Clin. Investig.* **1970**, *49*, 837–848. [[CrossRef](#)] [[PubMed](#)]
125. Sammons, M.F.; Lee, E.C. Recent progress in the development of small-molecule glucagon receptor antagonists. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 4057–4064. [[CrossRef](#)] [[PubMed](#)]
126. Kim, T.; Holleman, C.L.; Nason, S.; Arble, D.M.; Ottaway, N.; Chabenne, J.; Loyd, C.; Kim, J.A.; Sandoval, D.; Drucker, D.J.; et al. Hepatic Glucagon Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents. *Diabetes* **2018**, *67*, 2157–2166. [[CrossRef](#)] [[PubMed](#)]
127. Tan, T.M.; Field, B.C.; McCullough, K.A.; Troke, R.C.; Chambers, E.S.; Salem, V.; Gonzalez Maffe, J.; Baynes, K.C.; De Silva, A.; Viardot, A.; et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. *Diabetes* **2013**, *62*, 1131–1138. [[CrossRef](#)] [[PubMed](#)]
128. Hamberg, O.; Vilstrup, H. Regulation of urea synthesis by glucose and glucagon in normal man. *Clin. Nutr.* **1994**, *13*, 183–191. [[CrossRef](#)]
129. Snodgrass, P.J.; Lin, R.C.; Muller, W.A.; Aoki, T.T. Induction of urea cycle enzymes of rat liver by glucagon. *J. Biol. Chem.* **1978**, *253*, 2748–2753.
130. Vilstrup, H. On urea synthesis-regulation in vivo. *Dan. Med. Bull.* **1989**, *36*, 415–429.
131. Heibel, S.K.; Lopez, G.Y.; Panglao, M.; Sodha, S.; Marino-Ramirez, L.; Tuchman, M.; Caldovic, L. Transcriptional regulation of N-acetylglutamate synthase. *PLoS ONE* **2012**, *7*, e29527. [[CrossRef](#)]
132. Kilberg, M.S.; Barber, E.F.; Handlogten, M.E. Characteristics and hormonal regulation of amino acid transport system A in isolated rat hepatocytes. *Curr. Top. Cell. Regul.* **1985**, *25*, 133–163. [[PubMed](#)]

133. Nelson, D.L.; Lehninger, A.L.; Cox, M.M. *Lehninger Principles of Biochemistry*; W.H. Freeman: New York, NY, USA, 2008.
134. Morris, S.M., Jr. Regulation of enzymes of the urea cycle and arginine metabolism. *Annu. Rev. Nutr.* **2002**, *22*, 87–105. [[CrossRef](#)] [[PubMed](#)]
135. Galsgaard, K.D.; Winther-Sorensen, M.; Orskov, C.; Kissow, H.; Poulsen, S.S.; Vilstrup, H.; Prehn, C.; Adamski, J.; Jepsen, S.L.; Hartmann, B.; et al. Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis. *Am. J. Physiol. Endocrinol. Metab.* **2018**, *314*, E93–E103. [[CrossRef](#)] [[PubMed](#)]
136. Petersen, K.F.; Hansen, B.A.; Vilstrup, H. Time dependent stimulating effect of glucagon on the capacity of urea-N synthesis in rats. *Horm. Metab. Res.* **1987**, *19*, 53–56. [[CrossRef](#)] [[PubMed](#)]
137. Almdal, T.P.; Holst, J.J.; Heindorff, H.; Vilstrup, H. Glucagon immunoneutralization in diabetic rats normalizes urea synthesis and decreases nitrogen wasting. *Diabetes* **1992**, *41*, 12–16. [[CrossRef](#)]
138. Hamberg, O.; Vilstrup, H. Effects of insulin and glucose on urea synthesis in normal man, independent of pancreatic hormone secretion. *J. Hepatol.* **1994**, *21*, 381–387. [[CrossRef](#)]
139. Kraft, G.; Coate, K.C.; Winnick, J.J.; Dardevet, D.; Donahue, E.P.; Cherrington, A.D.; Williams, P.E.; Moore, M.C. Glucagon's effect on liver protein metabolism in vivo. *Am. J. Physiol. Endocrinol. Metab.* **2017**, *313*, E263–E272. [[CrossRef](#)]
140. Winther-Sørensen, M.; Galsgaard, K.D.; Kuhre, R.E.; Pedersen, J.; Wewer Albrechtsen, N.J.; Holst, J.J. Amino Acid Metabolism is Regulated by Glucagon Receptor Signaling in Mice. In Proceedings of the American Diabetes Association—78th Scientific Session, Orlando, FL, USA, 22–26 June 2018.
141. Dean, E.D.; Li, M.; Prasad, N.; Wisniewski, S.N.; Von Deylen, A.; Spaeth, J.; Maddison, L.; Botros, A.; Sedgeman, L.R.; Bozadjieva, N.; et al. Interrupted Glucagon Signaling Reveals Hepatic alpha Cell Axis and Role for L-Glutamine in alpha Cell Proliferation. *Cell Metab.* **2017**, *25*, 1362–1373. [[CrossRef](#)]
142. Solloway, M.J.; Madjidi, A.; Gu, C.; Eastham-Anderson, J.; Clarke, H.J.; Kljavin, N.; Zavala-Solorio, J.; Kates, L.; Friedman, B.; Brauer, M.; et al. Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of alpha-Cell Mass. *Cell Rep.* **2015**, *12*, 495–510. [[CrossRef](#)]
143. Charlton, M.R.; Adey, D.B.; Nair, K.S. Evidence for a catabolic role of glucagon during an amino acid load. *J. Clin. Investig.* **1996**, *98*, 90–99. [[CrossRef](#)]
144. Xiong, Y.; Guan, K.L. Mechanistic insights into the regulation of metabolic enzymes by acetylation. *J. Cell Biol.* **2012**, *198*, 155–164. [[CrossRef](#)] [[PubMed](#)]
145. Le Cam, A. Insulin and glucagon regulation of protein phosphorylation in isolated hepatocytes. Persistence, reversibility, and concentration dependence of hormonal effect. Evidence for common phosphorylation sites for both hormones on the Mr = 46,000 protein. *J. Biol. Chem.* **1982**, *257*, 8376–8389. [[PubMed](#)]
146. Nogueiras, R.; Habegger, K.M.; Chaudhary, N.; Finan, B.; Banks, A.S.; Dietrich, M.O.; Horvath, T.L.; Sinclair, D.A.; Pfluger, P.T.; Tschöp, M.H. Sirtuin 1 and sirtuin 3: Physiological modulators of metabolism. *Physiol. Rev.* **2012**, *92*, 1479–1514. [[CrossRef](#)] [[PubMed](#)]
147. Gebhardt, R.; Kleemann, E. Hormonal regulation of amino acid transport system N in primary cultures of rat hepatocytes. *Eur. J. Biochem.* **1987**, *166*, 339–344. [[CrossRef](#)] [[PubMed](#)]
148. Holst, J.J.; Christensen, M.; Lund, A.; de Heer, J.; Svendsen, B.; Kielgast, U.; Knop, F.K. Regulation of glucagon secretion by incretins. *Diabetes Obes. Metab.* **2011**, *13*, 89–94. [[CrossRef](#)] [[PubMed](#)]
149. Bonadonna, R.C.; Saccomani, M.P.; Cobelli, C.; DeFronzo, R.A. Effect of insulin on system A amino acid transport in human skeletal muscle. *J. Clin. Investig.* **1993**, *91*, 514–521. [[CrossRef](#)] [[PubMed](#)]
150. Longuet, C.; Robledo, A.M.; Dean, E.D.; Dai, C.; Ali, S.; McGuinness, I.; de Chavez, V.; Vuguin, P.M.; Charron, M.J.; Powers, A.C.; et al. Liver-specific disruption of the murine glucagon receptor produces alpha-cell hyperplasia: Evidence for a circulating alpha-cell growth factor. *Diabetes* **2013**, *62*, 1196–1205. [[CrossRef](#)] [[PubMed](#)]
151. Kim, J.; Dominguez Gutierrez, G.; Xin, Y.; Cavino, K.; Sung, B.; Sipos, B.; Kloeppel, G.; Gromada, J.; Okamoto, H. Increased SLC38A4 Amino Acid Transporter Expression in Human Pancreatic alpha-Cells After Glucagon Receptor Inhibition. *Endocrinology* **2019**, *160*, 979–988. [[CrossRef](#)] [[PubMed](#)]
152. Willcox, A.; Richardson, S.J.; Bone, A.J.; Foulis, A.K.; Morgan, N.G. Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes. *Diabetologia* **2010**, *53*, 2020–2028. [[CrossRef](#)]
153. Baron, A.D.; Schaeffer, L.; Shragg, P.; Kolterman, O.G. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. *Diabetes* **1987**, *36*, 274–283. [[CrossRef](#)]

154. Reaven, G.M.; Chen, Y.D.; Golay, A.; Swislocki, A.L.; Jaspan, J.B. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. *J. Clin. Endocrinol. Metab.* **1987**, *64*, 106–110. [[CrossRef](#)] [[PubMed](#)]
155. Wewer Albrechtsen, N.J.; Junker, A.E.; Christensen, M.; Haedersdal, S.; Wibrand, F.; Lund, A.M.; Galsgaard, K.D.; Holst, J.J.; Knop, F.K.; Vilsboll, T. Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2018**, *314*, G91–G96. [[CrossRef](#)] [[PubMed](#)]
156. Wewer Albrechtsen, N.J.; Faerch, K.; Jensen, T.M.; Witte, D.R.; Pedersen, J.; Mahendran, Y.; Jonsson, A.E.; Galsgaard, K.D.; Winther-Sorensen, M.; Torekov, S.S.; et al. Evidence of a liver- $\alpha$  cell axis in humans: Hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids. *Diabetologia* **2018**, *61*, 671–680. [[CrossRef](#)] [[PubMed](#)]
157. Gruppuso, P.A.; Susa, J.B.; Domenech, M.; Cha, C.J.; Schwartz, R. Chronic hyperglucagonemia in rats: Effects on insulin, substrates, and hepatic enzymes of intermediary metabolism. *Metabolism* **1983**, *32*, 911–918. [[CrossRef](#)]
158. Almdal, T.P.; Vilstrup, H. Exogenous hyperglucagonaemia in insulin controlled diabetic rats increases urea excretion and nitrogen loss from organs. *Diabetologia* **1988**, *31*, 836–841. [[CrossRef](#)] [[PubMed](#)]
159. Chastain, M.A. The glucagonoma syndrome: A review of its features and discussion of new perspectives. *Am. J. Med. Sci.* **2001**, *321*, 306–320. [[CrossRef](#)] [[PubMed](#)]
160. Mallinson, C.N.; Bloom, S.R.; Warin, A.P.; Salmon, P.R.; Cox, B. A glucagonoma syndrome. *Lancet (Lond. Engl.)* **1974**, *2*, 1–5. [[CrossRef](#)]
161. Marchesini, G.; Bianchi, G.P.; Vilstrup, H.; Checchia, G.A.; Patrono, D.; Zoli, M. Plasma clearances of branched-chain amino acids in control subjects and in patients with cirrhosis. *J. Hepatol.* **1987**, *4*, 108–117. [[CrossRef](#)]
162. Boden, G.; Rezvani, I.; Owen, O.E. Effects of glucagon on plasma amino acids. *J. Clin. Investig.* **1984**, *73*, 785–793. [[CrossRef](#)]
163. Almdal, T.P.; Heindorff, H.; Bardram, L.; Vilstrup, H. Increased amino acid clearance and urea synthesis in a patient with glucagonoma. *Gut* **1990**, *31*, 946–948. [[CrossRef](#)]
164. Kay, R.G.; Challis, B.G.; Casey, R.T.; Roberts, G.P.; Meek, C.L.; Reimann, F.; Gribble, F.M. Peptidomic analysis of endogenous plasma peptides from patients with pancreatic neuroendocrine tumours. *Rapid Commun. Mass Spectrom.* **2018**, *32*, 1414–1424. [[CrossRef](#)] [[PubMed](#)]
165. Norton, J.A.; Kahn, C.R.; Schiebinger, R.; Gorschboth, C.; Brennan, M.F. Amino acid deficiency and the skin rash associated with glucagonoma. *Ann. Intern. Med.* **1979**, *91*, 213–215. [[CrossRef](#)] [[PubMed](#)]
166. Alexander, E.K.; Robinson, M.; Staniec, M.; Dluhy, R.G. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. *Clin. Endocrinol.* **2002**, *57*, 827–831. [[CrossRef](#)]
167. Larger, E.; Wewer Albrechtsen, N.J.; Hansen, L.H.; Gelling, R.W.; Capeau, J.; Deacon, C.F.; Madsen, O.D.; Yakushiji, F.; De Meyts, P.; Holst, J.J.; et al. Pancreatic  $\alpha$ -cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation. *Endocrinol. Diabetes Metab. Case Rep.* **2016**. [[CrossRef](#)] [[PubMed](#)]
168. Zhou, C.; Dhall, D.; Nissen, N.N.; Chen, C.R.; Yu, R. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia,  $\alpha$  cell hyperplasia, and islet cell tumor. *Pancreas* **2009**, *38*, 941–946. [[CrossRef](#)] [[PubMed](#)]
169. Boden, G.; Master, R.W.; Rezvani, I.; Palmer, J.P.; Lobe, T.E.; Owen, O.E. Glucagon deficiency and hyperaminoacidemia after total pancreatectomy. *J. Clin. Investig.* **1980**, *65*, 706–716. [[CrossRef](#)] [[PubMed](#)]
170. Kim, J.Y.; Hickner, R.C.; Cortright, R.L.; Dohm, G.L.; Houmard, J.A. Lipid oxidation is reduced in obese human skeletal muscle. *Am. J. Physiol. Endocrinol. Metab.* **2000**, *279*, E1039–E1044. [[CrossRef](#)] [[PubMed](#)]
171. Stephens, F.B.; Constantin-Teodosiu, D.; Greenhaff, P.L. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. *J. Physiol.* **2007**, *581*, 431–444. [[CrossRef](#)]
172. DiMarco, J.P.; Hoppel, C. Hepatic mitochondrial function in ketogenic states. Diabetes, starvation, and after growth hormone administration. *J. Clin. Investig.* **1975**, *55*, 1237–1244. [[CrossRef](#)]
173. Berglund, E.D.; Lee-Young, R.S.; Lustig, D.G.; Lynes, S.E.; Donahue, E.P.; Camacho, R.C.; Meredith, M.E.; Magnuson, M.A.; Charron, M.J.; Wasserman, D.H. Hepatic energy state is regulated by glucagon receptor signaling in mice. *J. Clin. Investig.* **2009**, *119*, 2412–2422. [[CrossRef](#)]



174. Von Meyenn, F.; Porstmann, T.; Gasser, E.; Selevsek, N.; Schmidt, A.; Aebersold, R.; Stoffel, M. Glucagon-induced acetylation of Foxa2 regulates hepatic lipid metabolism. *Cell Metab.* **2013**, *17*, 436–447. [[CrossRef](#)] [[PubMed](#)]
175. Wolfrum, C.; Stoffel, M. Coactivation of Foxa2 through Pgc-1 $\beta$  promotes liver fatty acid oxidation and triglyceride/VLDL secretion. *Cell Metab.* **2006**, *3*, 99–110. [[CrossRef](#)] [[PubMed](#)]
176. Galsgaard, K.D.; Pedersen, J.; Knop, F.K.; Holst, J.J.; Wewer Albrechtsen, N.J. Glucagon Receptor Signaling and Lipid Metabolism. *Front. Physiol.* **2019**, *10*, 413. [[CrossRef](#)] [[PubMed](#)]
177. Guettet, C.; Mathe, D.; Riottot, M.; Lutton, C. Effects of chronic glucagon administration on cholesterol and bile acid metabolism. *Biochim. Biophys. Acta* **1988**, *963*, 215–223. [[CrossRef](#)]
178. Penhos, J.C.; Wu, C.H.; Daunas, J.; Reitman, M.; Levine, R. Effect of glucagon on the metabolism of lipids and on urea formation by the perfused rat liver. *Diabetes* **1966**, *15*, 740–748. [[CrossRef](#)] [[PubMed](#)]
179. Heimberg, M.; Weinstein, I.; Kohout, M. The effects of glucagon, dibutyryl cyclic adenosine 3',5'-monophosphate, and concentration of free fatty acid on hepatic lipid metabolism. *J. Biol. Chem.* **1969**, *244*, 5131–5139. [[PubMed](#)]
180. Eaton, R.P. Hypolipemic action of glucagon in experimental endogenous lipemia in the rat. *J. Lipid Res.* **1973**, *14*, 312–318.
181. Xiao, C.; Pavlic, M.; Szeto, L.; Patterson, B.W.; Lewis, G.F. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. *Diabetes* **2011**, *60*, 383–390. [[CrossRef](#)]
182. Prip-Buus, C.; Pegorier, J.P.; Duee, P.H.; Kohl, C.; Girard, J. Evidence that the sensitivity of carnitine palmitoyltransferase I to inhibition by malonyl-CoA is an important site of regulation of hepatic fatty acid oxidation in the fetal and newborn rabbit. Perinatal development and effects of pancreatic hormones in cultured rabbit hepatocytes. *Biochem. J.* **1990**, *269*, 409–415. [[CrossRef](#)]
183. Sloop, K.W.; Cao, J.X.; Siesky, A.M.; Zhang, H.Y.; Bodenmiller, D.M.; Cox, A.L.; Jacobs, S.J.; Moyers, J.S.; Owens, R.A.; Showalter, A.D.; et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. *J. Clin. Invest.* **2004**, *113*, 1571–1581. [[CrossRef](#)]
184. Liang, Y.; Osborne, M.C.; Monia, B.P.; Bhanot, S.; Gaarde, W.A.; Reed, C.; She, P.; Jetton, T.L.; Demarest, K.T. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. *Diabetes* **2004**, *53*, 410–417. [[CrossRef](#)] [[PubMed](#)]
185. Yang, J.; MacDougall, M.L.; McDowell, M.T.; Xi, L.; Wei, R.; Zavadoski, W.J.; Molloy, M.P.; Baker, J.D.; Kuhn, M.; Cabrera, O.; et al. Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: Implications on anti-glucagon therapies for diabetes. *BMC Genom.* **2011**, *12*, 281. [[CrossRef](#)] [[PubMed](#)]
186. Conarello, S.L.; Jiang, G.; Mu, J.; Li, Z.; Woods, J.; Zychband, E.; Ronan, J.; Liu, F.; Roy, R.S.; Zhu, L.; et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. *Diabetologia* **2007**, *50*, 142–150. [[CrossRef](#)] [[PubMed](#)]
187. Pocai, A.; Carrington, P.E.; Adams, J.R.; Wright, M.; Eiermann, G.; Zhu, L.; Du, X.; Petrov, A.; Lassman, M.E.; Jiang, G.; et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. *Diabetes* **2009**, *58*, 2258–2266. [[CrossRef](#)] [[PubMed](#)]
188. Day, J.W.; Ottaway, N.; Patterson, J.T.; Gelfanov, V.; Smiley, D.; Gidda, J.; Findeisen, H.; Bruemmer, D.; Drucker, D.J.; Chaudhary, N.; et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. *Nat. Chem. Biol.* **2009**, *5*, 749–757. [[CrossRef](#)]
189. More, V.R.; Lao, J.; McLaren, D.G.; Cumiskey, A.M.; Murphy, B.A.; Chen, Y.; Previs, S.; Stout, S.; Patel, R.; Satapati, S.; et al. Glucagon like receptor 1/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice. *PLoS ONE* **2017**, *12*, e0186586. [[CrossRef](#)] [[PubMed](#)]
190. Henderson, S.J.; Konkar, A.; Hornigold, D.C.; Trevaskis, J.L.; Jackson, R.; Fritsch Fredin, M.; Jansson-Lofmark, R.; Naylor, J.; Rossi, A.; Bednarek, M.A.; et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. *Diabetesobes. Metab.* **2016**, *18*, 1176–1190. [[CrossRef](#)]
191. Zhou, J.; Cai, X.; Huang, X.; Dai, Y.; Sun, L.; Zhang, B.; Yang, B.; Lin, H.; Huang, W.; Qian, H. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects. *Eur. J. Med. Chem.* **2017**, *138*, 1158–1169. [[CrossRef](#)]

192. Evers, A.; Haack, T.; Lorenz, M.; Bossart, M.; Elvert, R.; Henkel, B.; Stengelin, S.; Kurz, M.; Glien, M.; Dudda, A.; et al. Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. *J. Med. Chem.* **2017**, *60*, 4293–4303. [[CrossRef](#)]
193. Clemmensen, C.; Chabenne, J.; Finan, B.; Sullivan, L.; Fischer, K.; Kuchler, D.; Seher, L.; Ograjsek, T.; Hofmann, S.M.; Schriever, S.C.; et al. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. *Diabetes* **2014**, *63*, 1422–1427. [[CrossRef](#)]
194. Stralfors, P.; Bjorgell, P.; Belfrage, P. Hormonal regulation of hormone-sensitive lipase in intact adipocytes: Identification of phosphorylated sites and effects on the phosphorylation by lipolytic hormones and insulin. *Proc. Natl. Acad. Sci. USA* **1984**, *81*, 3317–3321. [[CrossRef](#)]
195. Garton, A.J.; Campbell, D.G.; Cohen, P.; Yeaman, S.J. Primary structure of the site on bovine hormone-sensitive lipase phosphorylated by cyclic AMP-dependent protein kinase. *FEBS Lett.* **1988**, *229*, 68–72. [[CrossRef](#)]
196. Anthonsen, M.W.; Ronnstrand, L.; Wernstedt, C.; Degerman, E.; Holm, C. Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. *J. Biol. Chem.* **1998**, *273*, 215–221. [[CrossRef](#)] [[PubMed](#)]
197. Greenberg, A.S.; Egan, J.J.; Wek, S.A.; Garty, N.B.; Blanchette-Mackie, E.J.; Londos, C. Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets. *J. Biol. Chem.* **1991**, *266*, 11341–11346. [[PubMed](#)]
198. Lass, A.; Zimmermann, R.; Haemmerle, G.; Riederer, M.; Schoiswohl, G.; Schweiger, M.; Kienesberger, P.; Strauss, J.G.; Gorkiewicz, G.; Zechner, R. Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome. *Cell Metab.* **2006**, *3*, 309–319. [[CrossRef](#)] [[PubMed](#)]
199. Granneman, J.G.; Moore, H.P.; Krishnamoorthy, R.; Rathod, M. Perilipin controls lipolysis by regulating the interactions of AB-hydrolase containing 5 (Abhd5) and adipose triglyceride lipase (Atgl). *J. Biol. Chem.* **2009**, *284*, 34538–34544. [[CrossRef](#)] [[PubMed](#)]
200. Egan, J.J.; Greenberg, A.S.; Chang, M.K.; Wek, S.A.; Moos, M.C., Jr.; Londos, C. Mechanism of hormone-stimulated lipolysis in adipocytes: Translocation of hormone-sensitive lipase to the lipid storage droplet. *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 8537–8541. [[CrossRef](#)] [[PubMed](#)]
201. Shen, W.J.; Patel, S.; Miyoshi, H.; Greenberg, A.S.; Kraemer, F.B. Functional interaction of hormone-sensitive lipase and perilipin in lipolysis. *J. Lipid Res.* **2009**, *50*, 2306–2313. [[CrossRef](#)] [[PubMed](#)]
202. Wang, H.; Hu, L.; Dalen, K.; Dorward, H.; Marcinkiewicz, A.; Russell, D.; Gong, D.; Londos, C.; Yamaguchi, T.; Holm, C.; et al. Activation of hormone-sensitive lipase requires two steps, protein phosphorylation and binding to the PAT-1 domain of lipid droplet coat proteins. *J. Biol. Chem.* **2009**, *284*, 32116–32125. [[CrossRef](#)]
203. Schweiger, M.; Eichmann, T.O.; Taschler, U.; Zimmermann, R.; Zechner, R.; Lass, A. Measurement of lipolysis. *Methods Enzymol.* **2014**, *538*, 171–193. [[CrossRef](#)]
204. Hansen, L.H.; Abrahamsen, N.; Nishimura, E. Glucagon receptor mRNA distribution in rat tissues. *Peptides* **1995**, *16*, 1163–1166. [[CrossRef](#)]
205. Svoboda, M.; Tastenoy, M.; Vertongen, P.; Robberecht, P. Relative quantitative analysis of glucagon receptor mRNA in rat tissues. *Mol. Cell. Endocrinol.* **1994**, *105*, 131–137. [[CrossRef](#)]
206. Slavin, B.G.; Ong, J.M.; Kern, P.A. Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. *J. Lipid Res.* **1994**, *35*, 1535–1541. [[PubMed](#)]
207. Vaughan, M.; Berger, J.E.; Steinberg, D. Hormone-Sensitive Lipase and Monoglyceride Lipase Activities in Adipose Tissue. *J. Biol. Chem.* **1964**, *239*, 401–409. [[PubMed](#)]
208. Rodbell, M.; Jones, A.B. Metabolism of isolated fat cells. 3. The similar inhibitory action of phospholipase C (*Clostridium perfringens* alpha toxin) and of insulin on lipolysis stimulated by lipolytic hormones and theophylline. *J. Biol. Chem.* **1966**, *241*, 140–142. [[PubMed](#)]
209. Prigge, W.F.; Grande, F. Effects of glucagon, epinephrine and insulin on in vitro lipolysis of adipose tissue from mammals and birds. *Comp. Biochem. Physiol. B Comp. Biochem.* **1971**, *39*, 69–82. [[CrossRef](#)]
210. Vaughan, M.; Steinberg, D. Effect of hormones on lipolysis and esterification of free fatty acids during incubation of adipose tissue in vitro. *J. Lipid Res.* **1963**, *4*, 193–199.
211. Manganiello, V.; Vaughan, M. Selective loss of adipose cell responsiveness to glucagon with growth in the rat. *J. Lipid Res.* **1972**, *13*, 12–16.
212. Livingston, J.N.; Cuatrecasas, P.; Lockwood, D.H. Studies of glucagon resistance in large rat adipocytes: 125I-labeled glucagon binding and lipolytic capacity. *J. Lipid Res.* **1974**, *15*, 26–32.



213. Lefebvre, P.; Luyckx, A.; Bacq, Z.M. Effects of denervation on the metabolism and the response to glucagon of white adipose tissue of rats. *Horm. Metab. Res. Metab.* **1973**, *5*, 245–250. [\[CrossRef\]](#)
214. Honnor, R.C.; Dhillon, G.S.; Londos, C. cAMP-dependent protein kinase and lipolysis in rat adipocytes. I. Cell preparation, manipulation, and predictability in behavior. *J. Biol. Chem.* **1985**, *260*, 15122–15129. [\[PubMed\]](#)
215. Mosinger, B.; Kuhn, E.; Kujalova, V. Action of adipokinetic hormones on human adipose tissue in vitro. *J. Lab. Clin. Med.* **1965**, *66*, 380–389. [\[PubMed\]](#)
216. Vizek, K.; Razova, M.; Melichar, V. Lipolytic effect of TSH, glucagon and hydrocortisone on the adipose tissue of newborns and adults in vitro. *Physiol. Bohemoslov.* **1979**, *28*, 325–331. [\[PubMed\]](#)
217. Gravholt, C.H.; Moller, N.; Jensen, M.D.; Christiansen, J.S.; Schmitz, O. Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. *J. Clin. Endocrinol. Metab.* **2001**, *86*, 2085–2089. [\[CrossRef\]](#) [\[PubMed\]](#)
218. Pozza, G.; Pappalettera, A.; Melogli, O.; Viberti, G.; Ghidoni, A. Lipolytic effect of intra-arterial injection of glucagon in man. *Horm. Metab. Res. Metab.* **1971**, *3*, 291–292. [\[CrossRef\]](#)
219. Pozefsky, T.; Tancredi, R.G.; Moxley, R.T.; Dupre, J.; Tobin, J.D. Metabolism of forearm tissues in man. Studies with glucagon. *Diabetes* **1976**, *25*, 128–135. [\[CrossRef\]](#) [\[PubMed\]](#)
220. Jensen, M.D.; Heiling, V.J.; Miles, J.M. Effects of glucagon on free fatty acid metabolism in humans. *J. Clin. Endocrinol. Metab.* **1991**, *72*, 308–315. [\[CrossRef\]](#)
221. Wu, M.S.; Jeng, C.Y.; Hollenbeck, C.B.; Chen, Y.D.; Jaspan, J.; Reaven, G.M. Does glucagon increase plasma free fatty acid concentration in humans with normal glucose tolerance? *J. Clin. Endocrinol. Metab.* **1990**, *70*, 410–416. [\[CrossRef\]](#)
222. Schade, D.S.; Eaton, R.P. Modulation of fatty acid metabolism by glucagon in man. I. Effects in normal subjects. *Diabetes* **1975**, *24*, 502–509. [\[CrossRef\]](#)
223. Schneider, S.H.; Fineberg, S.E.; Blackburn, G.L. The acute metabolic effects of glucagon and its interactions with insulin in forearm tissue. *Diabetologia* **1981**, *20*, 616–621. [\[CrossRef\]](#)
224. Lefebvre, P.J.; Luyckx, A.S. Glucagon and Catecholamines. In *Glucagon II*; Lefebvre, P.J., Ed.; Springer: Berlin/Heidelberg, Germany, 1983; pp. 537–543.
225. Liljenquist, J.E.; Bomboy, J.D.; Lewis, S.B.; Sinclair-Smith, B.C.; Felts, P.W.; Lacy, W.W.; Crofford, O.B.; Liddle, G.W. Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. *J. Clin. Investig.* **1974**, *53*, 190–197. [\[CrossRef\]](#) [\[PubMed\]](#)
226. Goldfine, I.D.; Cerasi, E.; Luft, R. Glucagon Stimulation of Insulin Release in Man: Inhibition during Hypoglycemia. *J. Clin. Endocrinol. Metab.* **1972**, *35*, 312–315. [\[CrossRef\]](#) [\[PubMed\]](#)
227. Samols, E.; Marri, G.; Marks, V. Promotion of insulin secretion by glucagon. *Lancet (Lond. Engl.)* **1965**, *2*, 415–416. [\[CrossRef\]](#)
228. Gerich, J.E.; Lorenzi, M.; Bier, D.M.; Tsalikian, E.; Schneider, V.; Karam, J.H.; Forsham, P.H. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. *J. Clin. Investig.* **1976**, *57*, 875–884. [\[CrossRef\]](#) [\[PubMed\]](#)
229. Lefebvre, P.J.; Luyckx, A.S. Effect of insulin on glucagon enhanced lipolysis in vitro. *Diabetologia* **1969**, *5*, 195–197. [\[CrossRef\]](#) [\[PubMed\]](#)
230. Carlson, M.G.; Snead, W.L.; Campbell, P.J. Regulation of free fatty acid metabolism by glucagon. *J. Clin. Endocrinol. Metab.* **1993**, *77*, 11–15. [\[CrossRef\]](#) [\[PubMed\]](#)
231. Lizarraga-Mollinedo, E.; Fernández-Millán, E.; Martín, J.d.T.; Martínez-Hondurilla, C.; Escrivá, F.; Álvarez, C. Early undernutrition induces glucagon resistance and insulin hypersensitivity in the liver of suckling rats. *Am. J. Physiol. Endocrinol. Metab.* **2012**, *302*, E1070–E1077. [\[CrossRef\]](#) [\[PubMed\]](#)
232. Charbonneau, A.; Melancon, A.; Lavoie, C.; Lavoie, J.M. Alterations in hepatic glucagon receptor density and in Gsalpha and Gialpha2 protein content with diet-induced hepatic steatosis: Effects of acute exercise. *Am. J. Physiol. Endocrinol. Metab.* **2005**, *289*, E8–E14. [\[CrossRef\]](#) [\[PubMed\]](#)
233. De Chiara, F.; Heeboll, S.; Marrone, G.; Montoliu, C.; Hamilton-Dutoit, S.; Ferrandez, A.; Andreola, F.; Rombouts, K.; Gronbaek, H.; Felipe, V.; et al. Urea cycle dysregulation in non-alcoholic fatty liver disease. *J. Hepatol.* **2018**, *69*, 905–915. [\[CrossRef\]](#)
234. Glavind, E.; Aagaard, N.K.; Gronbaek, H.; Moller, H.J.; Orntoft, N.W.; Vilstrup, H.; Thomsen, K.L. Alcoholic Hepatitis Markedly Decreases the Capacity for Urea Synthesis. *PLoS ONE* **2016**, *11*, e0158388. [\[CrossRef\]](#)

235. Cheng, X.; Kim, S.Y.; Okamoto, H.; Xin, Y.; Yancopoulos, G.D.; Murphy, A.J.; Gromada, J. Glucagon contributes to liver zonation. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E4111–E4119. [[CrossRef](#)] [[PubMed](#)]
236. Savage, A.; Zeng, L.; Houslay, M.D. A role for protein kinase C-mediated phosphorylation in eliciting glucagon desensitization in rat hepatocytes. *Biochem. J.* **1995**, *307*, 281–285. [[CrossRef](#)] [[PubMed](#)]
237. Authier, F.; Desbuquois, B.; De Galle, B. Ligand-mediated internalization of glucagon receptors in intact rat liver. *Endocrinology* **1992**, *131*, 447–457. [[CrossRef](#)] [[PubMed](#)]
238. Krilov, L.; Nguyen, A.; Miyazaki, T.; Unson, C.G.; Williams, R.; Lee, N.H.; Ceryak, S.; Bouscarel, B. Dual mode of glucagon receptor internalization: Role of PKC $\alpha$ , GRKs and beta-arrestins. *Exp. Cell Res.* **2011**, *317*, 2981–2994. [[CrossRef](#)] [[PubMed](#)]
239. Krilov, L.; Nguyen, A.; Miyazaki, T.; Unson, C.G.; Bouscarel, B. Glucagon receptor recycling: Role of carboxyl terminus, beta-arrestins, and cytoskeleton. *Am. J. Physiol. Cell Physiol.* **2008**, *295*, C1230–C1237. [[CrossRef](#)] [[PubMed](#)]
240. Elkeles, R.S.; Hambley, J. Glucagon resistance as a cause of hypertriglyceride. *Lancet* **1976**, *308*, 18–20. [[CrossRef](#)]
241. Suppli, M.P.; Lund, A.; Bagger, J.I.; Vilsboll, T.; Knop, F.K. Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia. *Med. Hypotheses* **2016**, *86*, 100–103. [[CrossRef](#)]
242. Haidar, A.; Legault, L.; Messier, V.; Mitre, T.M.; Leroux, C.; Rabasa-Lhoret, R. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: An open-label randomised controlled crossover trial. *Lancet Diabetes Endocrinol.* **2015**, *3*, 17–26. [[CrossRef](#)]
243. Finan, B.; Capozzi, M.E.; Campbell, J.E. Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes. *Diabetes* **2019**, *68*. [[CrossRef](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).